D	C177536	GDC Property Terminology	C111028	Extrascleral Extension of Uveal Melanoma	Spread of uveal melanoma beyond the sclera.	extrascleral_extension	extrascleral extension
D	C177536	GDC Property Terminology	C139577	Stage R	A general term that refers to the histopathological staging of residual tumors after treatment.	residual_tumor	residual tumor
D	C177536	GDC Property Terminology	C181721	Age at Undescended Testis Correction	The age of the subject when undescended testis was corrected.	undescended_testis_corrected_age	undescended testis corrected age
D	C177536	GDC Property Terminology	C200471	Percent of Epithelioid Melanocytes	A quantitative measurement of the percent of epithelioid melanocytes compared to the number of total cells present in a sample.	epithelioid_cell_percent	epithelioid cell percent
D	C177536	GDC Property Terminology	C200472	Percent of Spindle-Shaped Melanocytes	A quantitative measurement of the percent of spindle-shaped melanocytes compared to the number of total cells present in a sample.	spindle_cell_percent	spindle cell percent
A	C177536	GDC Property Terminology	C103339	Pretreatment	Any relevant actions that were performed or occurred prior to a specific treatment.	pretreatment	
A	C177536	GDC Property Terminology	C111067	Testicular Cancer Serum Markers Test Result	A laboratory test result in which markers for testicular cancer are tested in a blood sample for staging purposes.	ajcc_serum_tumor_markers	ajcc serum tumor markers
A	C177536	GDC Property Terminology	C17005	Population Group	A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender)	population_group	population group
A	C177536	GDC Property Terminology	C211836	Histological Progression Indicator	An indication as to whether a subject has a progressive disease based on histological analysis.	histologic_progression	histologic progression
A	C177536	GDC Property Terminology	C211838	Undescended Testis Corrected Age Range	The age range a subject had a procedure to correct undescended testis.	undescended_testis_corrected_age_range	undescended testis corrected age range
A	C177536	GDC Property Terminology	C211839	Epithelioid Cell Percent Range	A semi-quantitative measurement represented as the range of percent values for epithlioid melanocytes compared to the number of total cells present in a sample.	epithelioid_cell_percent_range	epithelioid cell percent range
A	C177536	GDC Property Terminology	C211840	Extrascleral Extension Present Indicator	An indication of whether extrascleral extension of uveal melanoma is present in a sample.	extrascleral_extension_present	extrascleral extension present
A	C177536	GDC Property Terminology	C211841	Intratubular Germ Cell Neoplasia Present Indicator	An indication of whether intratubular germ cell neoplasia is present in a sample.	intratubular_germ_cell_neoplasia_present	intratubular germ cell neoplasia present
A	C177536	GDC Property Terminology	C211842	Spindle Cell Percent Range	A semi-quantitative measurement represented as the range of percent values for spindle-shaped melanocytes compared to the number of total cells present in a sample.	spindle_cell_percent_range	spindle cell percent range
A	C177536	GDC Property Terminology	C211844	Tumor Basal Diameter	The diameter of the lowest layer of a tumor.	tumor_basal_diameter	tumor basal diameter
A	C177536	GDC Property Terminology	C211845	Primary Disease Diagnosis Submitter Identifier	The string that identifies the submitter of the primary diagnosis.	tumor_of_origin	tumor of origin
C	C177536	GDC Property Terminology	C177618	Library Sequencing	The method used to determine the order of purines and pyrimidines in a nucleic acid-based sequencing library.	library_strategy	library strategy
C	C177536	GDC Property Terminology	C185261	Extraocular Nodule Size	The dimensions of a nodule found near but outside the eye.	extraocular_nodule_size	extraocular nodule size
C	C177536	GDC Property Terminology	C19770	Molecular Analysis	A laboratory procedure that involves the study of tissues, cells, and fluids using techniques to analyze biologically active molecules, including nucleic acids, proteins, lipids and carbohydrates, for the identification of processes, characteristics and abnormalities at the molecular level.	molecular_analysis_method	molecular analysis method
C	C177536	GDC Property Terminology	C198198	Therapeutic Agent Level Achieved Indicator	An indication that the intended level of therapeutic agent was achieved in an individual.	therapeutic_levels_achieved	therapeutic levels achieved
C	C177536	GDC Property Terminology	C25218	Clinical Intervention or Procedure	An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.	treatment_type	treatment type
C	C177536	GDC Property Terminology	C4809	Residual Disease	The persistence of tumor cells in the body following cancer treatment.	residual_disease || residual_tumor	residual disease || residual tumor
D	C177537	GDC Value Terminology	C154329	Smoking	The act of puffing and/or inhaling the combustion products of a substance so as to be tasted and absorbed into the bloodstream.	Smoking | comorbidities	C16457	comorbidities
D	C177537	GDC Value Terminology	C9063	Malignant Testicular Germ Cell Tumor	A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.	Testicular Cancer | relationship_primary_diagnosis	C178243	relationship_primary_diagnosis
A	C177537	GDC Value Terminology	C111068	SX	Marker studies not available or not performed. (AJCC 7th ed.)	SX | ajcc_serum_tumor_markers	C111067	ajcc_serum_tumor_markers
A	C177537	GDC Value Terminology	C111069	S0	Marker study levels within normal limits. (AJCC 7th ed.)	S0 | ajcc_serum_tumor_markers	C111067	ajcc_serum_tumor_markers
A	C177537	GDC Value Terminology	C111070	S1	LDH less than 1.5 x N and hCG (mIu/ml) less than 5,000 and AFP (ng/ml) less than 1,000.  N indicates the upper limit of normal for the LDH assay. (AJCC 7th ed.)	S1 | ajcc_serum_tumor_markers	C111067	ajcc_serum_tumor_markers
A	C177537	GDC Value Terminology	C111071	S2	LDH 1.5-10 x N or hCG (mIu/ml) 5,000-50,000 or AFP (ng/ml) 1,000-10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 7th ed.)	S2 | ajcc_serum_tumor_markers	C111067	ajcc_serum_tumor_markers
A	C177537	GDC Value Terminology	C111072	S3	LDH more than 10 x N or hCG (mIu/ml) more than 50,000 or AFP (ng/ml) more than 10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 7th ed.)	S3 | ajcc_serum_tumor_markers	C111067	ajcc_serum_tumor_markers
A	C177537	GDC Value Terminology	C113426	Twelve	A natural number greater than 11 and less than 13 and the quantity that it denotes.	12 | mutation_codon	C198131	mutation_codon
A	C177537	GDC Value Terminology	C113427	Thirteen	A natural number greater than 12 and less than 14 and the quantity that it denotes.	13 | mutation_codon	C198131	mutation_codon
A	C177537	GDC Value Terminology	C118955	Low Mitosis-Karyorrhexis Index	An index used in neuroblastic tumors indicating the presence of less than 100 mitoses and karyorrhexis per 5,000 cells.	Low | mitosis_karyorrhexis_index	C106317	mitosis_karyorrhexis_index
A	C177537	GDC Value Terminology	C118957	Intermediate Mitosis-Karyorrhexis Index	An index used in neuroblastic tumors indicating the presence of between 100 and 200 mitoses and karyorrhexis per 5,000 cells.	Intermediate | mitosis_karyorrhexis_index	C106317	mitosis_karyorrhexis_index
A	C177537	GDC Value Terminology	C118958	High Mitosis-Karyorrhexis Index	An index used in neuroblastic tumors indicating the presence of more than 200 mitoses and karyorrhexis per 5,000 cells.	High | mitosis_karyorrhexis_index	C106317	mitosis_karyorrhexis_index
A	C177537	GDC Value Terminology	C1198	Poly ICLC	A synthetic complex of carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA. Poly ICLC may stimulate the release of cytotoxic cytokines and, by inducing interferon-gamma production, may increase the tumoricidal activities of various immunohematopoietic cells. (NCI04)	Poly ICLC | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C12709	Epiglottis	A small cartilagenous flap-like valve that closes over the larynx during swallowing to prevent food entering the lungs.	Epiglottis | treatment_anatomic_sites	C70729	treatment_anatomic_sites
A	C177537	GDC Value Terminology	C12737	Iris	The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber.	Eye, Iris | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C15359	Salvage Therapy	Performing a salvage procedure is the last resort. The clinical situation involves either ongoing life support measures, life support measures for more than 60 seconds during the prior 10 minutes, or unanticipated institution of extracorporeal circulatory support. (ACC)	Salvage | treatment_intent_type	C54398	treatment_intent_type
A	C177537	GDC Value Terminology	C156054	Human Papillomavirus-63	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-63 may be associated with a risk for cervical cancer.	HPV63 | hpv_strain	C157110	hpv_strain
A	C177537	GDC Value Terminology	C156055	Human Papillomavirus-70	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-70 may be associated with a high risk for cervical cancer.	HPV70 | hpv_strain	C157110	hpv_strain
A	C177537	GDC Value Terminology	C1600	Cidofovir	A synthetic, acyclic, monophosphate nucleotide analog of deoxycytidine with antiviral activity, and mostly used against cytomegalovirus (CMV). After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses.	Cidofovir | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C161380	Skin of the Inguinal Region	The integument that covers the inguinal region.	Skin, Groin | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C17950	Ashkenazi Jew	Ashkenazi Jews, also called Ashkenazim, are Jews who are descendants of Jews from Germany, Poland, Austria and Eastern Europe.	Ashkenazi Jew | population_group	C17005	population_group
A	C177537	GDC Value Terminology	C188325	Sixty One	The natural number greater than sixty and less than sixty-two and the quantity that it denotes.	61 | mutation_codon	C198131	mutation_codon
A	C177537	GDC Value Terminology	C194295	Malignant Neoplasm of Upper-Inner Quadrant of Right Female Breast	Evidence of a malignant neoplasm of the upper-inner quadrant of right female breast.	Breast, Right Upper Inner | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194296	Malignant Neoplasm of Upper-Inner Quadrant of Left Female Breast	Evidence of a malignant neoplasm of the upper-inner quadrant of left female breast.	Breast, Left Upper Inner | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194298	Malignant Neoplasm of Upper-Inner Quadrant of Right Male Breast	Evidence of a malignant neoplasm of the upper-inner quadrant of right male breast.	Breast, Right Upper Inner | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194299	Malignant Neoplasm of Upper-Inner Quadrant of Left Male Breast	Evidence of a malignant neoplasm of the upper-inner quadrant of left male breast.	Breast, Left Upper Inner | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194301	Malignant Neoplasm of Lower-Inner Quadrant of Right Female Breast	Evidence of a malignant neoplasm of the lower-inner quadrant of right female breast.	Breast, Right Lower Inner | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194302	Malignant Neoplasm of Lower-Inner Quadrant of Left Female Breast	Evidence of a malignant neoplasm of the lower-inner quadrant of left female breast.	Breast, Left Lower Inner | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194304	Malignant Neoplasm of Lower-Inner Quadrant of Right Male Breast	Evidence of a malignant neoplasm of the lower-inner quadrant of right male breast.	Breast, Right Lower Inner | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194305	Malignant Neoplasm of Lower-Inner Quadrant of Left Male Breast	Evidence of a malignant neoplasm of the lower-inner quadrant of left male breast.	Breast, Left Lower Inner | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194307	Malignant Neoplasm of Upper-Outer Quadrant of Right Female Breast	Evidence of a malignant neoplasm of the upper-outer quadrant of right female breast.	Breast, Right Upper Outer | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194308	Malignant Neoplasm of Upper-Outer Quadrant of Left Female Breast	Evidence of a malignant neoplasm of the upper-outer quadrant of left female breast.	Breast, Left Upper Outer | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194310	Malignant Neoplasm of Upper-Outer Quadrant of Right Male Breast	Evidence of a malignant neoplasm of the upper-outer quadrant of right male breast.	Breast, Right Upper Outer | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194311	Malignant Neoplasm of Upper-Outer Quadrant of Left Male Breast	Evidence of a malignant neoplasm of the upper-outer quadrant of left male breast.	Breast, Left Upper Outer | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194313	Malignant Neoplasm of Lower-Outer Quadrant of Right Female Breast	Evidence of a malignant neoplasm of the lower-outer quadrant of right female breast.	Breast, Right Lower Outer | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194314	Malignant Neoplasm of Lower-Outer Quadrant of Left Female Breast	Evidence of a malignant neoplasm of the lower-outer quadrant of left female breast.	Breast, Left Lower Outer | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194316	Malignant Neoplasm of Lower-Outer Quadrant of Right Male Breast	Evidence of a malignant neoplasm of the lower-outer quadrant of right male breast.	Breast, Right Lower Outer | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C194317	Malignant Neoplasm of Lower-Outer Quadrant of Left Male Breast	Evidence of a malignant neoplasm of the lower-outer quadrant of left male breast.	Breast, Left Lower Outer | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C208260	pT1c2 TNM Finding	A pathologic TNM finding of a primary tumor. The definition of pT1c2 finding depends on the particular type of cancer that it refers to; for example, for ovarian, fallopian tube, and primary peritoneal carcinoma pT1c2 is defined as follows: carcinoma limited to one or both ovaries or fallopian tubes, with capsule ruptured before surgery or tumor on ovarian or fallopian tube surface. (from AJCC 8th Ed.)	T1c2 | ajcc_pathologic_t || T1c2 | uicc_pathologic_t	C177636 || C188448	ajcc_pathologic_t || uicc_pathologic_t
A	C177537	GDC Value Terminology	C211846	Lesion Less than or Equal to 5 mm in Diameter	A semi-quantitative finding indicating that the largest diameter for a lesion was at most 5 mm.	<=5mm | extraocular_nodule_size	C185261	extraocular_nodule_size
A	C177537	GDC Value Terminology	C211847	Lesion Greater than 5 mm in Diameter	A semi-quantitative finding indicating that the largest diameter for a lesion was greater than 5 mm.	>5mm | extraocular_nodule_size	C185261	extraocular_nodule_size
A	C177537	GDC Value Terminology	C211848	Bladder Involvement	A finding indicating the spread of disease to the bladder.	Bladder Involvement | imaging_findings	C199145	imaging_findings
A	C177537	GDC Value Terminology	C211849	Extra-Pelvic Metastatic Disease	A finding indicating the spread of cancer cells outside the pelvic region.	Extra-Pelvic Metastatic Disease | imaging_findings	C199145	imaging_findings
A	C177537	GDC Value Terminology	C211850	Paraaortic Lymph Node Involvement	A finding indicating the spread of disease to para-aortic lymph nodes.	Paraaortic Lymph Node Involvement | imaging_findings	C199145	imaging_findings
A	C177537	GDC Value Terminology	C211851	Parametrium Involvement	A finding indicating the spread of disease to the parametrium.	Parametrium Involvement | imaging_findings	C199145	imaging_findings
A	C177537	GDC Value Terminology	C211852	Pelvic Lymph Node Involvement	A finding indicating the spread of disease to pelvic lymph nodes.	Pelvic Lymph Node Involvement | imaging_findings	C199145	imaging_findings
A	C177537	GDC Value Terminology	C211853	Supraclavicular Lymph Node Involvement	A finding indicating the spread of disease to supraclavicular lymph nodes.	Supraclavicular Lymph Node Involvement | imaging_findings	C199145	imaging_findings
A	C177537	GDC Value Terminology	C211854	Pregnancy in Patient or Partner Indicator	An indication that the subject or their partner are pregnant.	Pregnancy in Patient or Partner | risk_factors	C17103	risk_factors
A	C177537	GDC Value Terminology	C211855	After Chemotherapy	Relating to or occurring after the administration of chemotherapy.	After Chemotherapy | timepoint_category	C198201	timepoint_category
A	C177537	GDC Value Terminology	C211857	After Enrollment	Relating to or occurring after enrollment into a study or trial.	After Study Enrollment | timepoint_category	C198201	timepoint_category
A	C177537	GDC Value Terminology	C211858	Post Initial Treatment	Relating to or occurring after an initial treatment procedure.	Post Initial Treatment | timepoint_category	C198201	timepoint_category
A	C177537	GDC Value Terminology	C211859	Prior to Chemotherapy	Relating to or occurring before the administration of chemotherapy.	Prior to Chemotherapy | timepoint_category	C198201	timepoint_category
A	C177537	GDC Value Terminology	C211860	Pre-Enrollment	Relating to or occurring before enrollment into a study or trial.	Prior to Study Enrollment | timepoint_category	C198201	timepoint_category
A	C177537	GDC Value Terminology	C211876	Pre-Procedure Thyroid Hormone Therapy Withdrawal	Discontinuation of thyroid hormone replacement therapy prior to either radioablation therapy or screening for residual/recurrent thyroid cancer.	Thyroxine Withdrawal | pretreatment	C103339	pretreatment
A	C177537	GDC Value Terminology	C211884	Test Value Result Range Greater than 90 Percent	A range of test result values greater than 90 percent.	>90% | epithelioid_cell_percent_range || >90% | spindle_cell_percent_range	C211839 || C211842	epithelioid_cell_percent_range || spindle_cell_percent_range
A	C177537	GDC Value Terminology	C211885	Test Value Result Range 1 to 30 Percent	A range of test result values greater than or equal to 1 percent and less than or equal to 30 percent.	1-30% | epithelioid_cell_percent_range || 1-30% | spindle_cell_percent_range	C211839 || C211842	epithelioid_cell_percent_range || spindle_cell_percent_range
A	C177537	GDC Value Terminology	C211886	Test Value Result Range 31 to 60 Percent	A range of test result values greater than or equal to 31 percent and less than or equal to 60 percent.	31-60% | epithelioid_cell_percent_range || 31-60% | spindle_cell_percent_range	C211839 || C211842	epithelioid_cell_percent_range || spindle_cell_percent_range
A	C177537	GDC Value Terminology	C211887	Test Value Result Range 61 to 90 Percent	A range of test result values greater than or equal to 61 percent and less than or equal to 90 percent.	61-90% | epithelioid_cell_percent_range || 61-90% | spindle_cell_percent_range	C211839 || C211842	epithelioid_cell_percent_range || spindle_cell_percent_range
A	C177537	GDC Value Terminology	C211888	Test Value Result Range 1 to 4 Percent	A range of test result values greater than or equal to 1 percent and less than or equal to 4 percent.	1-4% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211889	Test Value Result Range 5 to 9 Percent	A range of test result values greater than or equal to 5 percent and less than or equal to 9 percent.	5-9% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211890	Test Value Result Range Less than 1 Percent	A range of test result values less than 1 percent.	<1% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211891	Test Value Result Range Less than 10 Percent	A range of test result values less than 10 percent.	<10% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211892	Test Value Result Range Greater than or Equal to 50 Percent	A range of test result values greater than or equal to 50 percent.	>=50% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211893	Test Value Result Range 0 to 25 Percent	A range of test result values greater than or equal to 0 percent and less than or equal to 25 percent.	0-25% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211894	Test Value Result Range 1 to 49 Percent	A range of test result values greater than or equal to 1 percent and less than or equal to 49 percent.	1-49% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211895	Test Value Result Range 10 to 19 Percent	A range of test result values greater than or equal to 10 percent and less than or equal to 19 percent.	10-19% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211896	Test Value Result Range 20 to 29 Percent	A range of test result values greater than or equal to 20 percent and less than or equal to 29 percent.	20-29% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211897	Test Value Result Range 26 to 50 Percent	A range of test result values greater than or equal to 26 percent and less than or equal to 50 percent.	26-50% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211898	Test Value Result Range 30 to 39 Percent	A range of test result values greater than or equal to 30 percent and less than or equal to 39 percent.	30-39% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211899	Test Value Result Range 40 to 49 Percent	A range of test result values greater than or equal to 40 percent and less than or equal to 49 percent.	40-49% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211900	Test Value Result Range 50 to 59 Percent	A range of test result values greater than or equal to 50 percent and less than or equal to 59 percent.	50-59% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211901	Test Value Result Range 51 to 75 Percent	A range of test result values greater than or equal to 51 percent and less than or equal to 75 percent.	51-75% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211902	Test Value Result Range 60 to 69 Percent	A range of test result values greater than or equal to 60 percent and less than or equal to 69 percent.	60-69% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211903	Test Value Result Range 70 to 79 Percent	A range of test result values greater than or equal to 70 percent and less than or equal to 79 percent.	70-79% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211904	Test Value Result Range 76 to 100 Percent	A range of test result values greater than or equal to 76 percent and less than or equal to 100 percent.	76-100% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211905	Test Value Result Range 80 to 89 Percent	A range of test result values greater than or equal to 80 percent and less than or equal to 89 percent.	80-89% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211906	Test Value Result Range 90 to 99 Percent	A range of test result values greater than or equal to 90 percent and less than or equal to 99 percent.	90-99% | test_value_range	C198199	test_value_range
A	C177537	GDC Value Terminology	C211907	Age Range of 10 to 14 Years	An individual of at least 10 years to at most 14 years of age.	10-14 years | undescended_testis_corrected_age_range	C211838	undescended_testis_corrected_age_range
A	C177537	GDC Value Terminology	C211908	Age Range of 1 to 2 Years	An individual of at least 1 years to at most 2 years of age.	1-2 years | undescended_testis_corrected_age_range	C211838	undescended_testis_corrected_age_range
A	C177537	GDC Value Terminology	C211910	Age Range of 2 to 11 Months	An individual of at least 2 months to at most 11 months of age.	2-11 months | undescended_testis_corrected_age_range	C211838	undescended_testis_corrected_age_range
A	C177537	GDC Value Terminology	C211911	Age Range of 3 to 9 Years	An individual of at least 3 years to at most 9 years of age.	3-9 years | undescended_testis_corrected_age_range	C211838	undescended_testis_corrected_age_range
A	C177537	GDC Value Terminology	C26845	Parkinson Disease	A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.	Parkinson's Disease | comorbidities	C16457	comorbidities
A	C177537	GDC Value Terminology	C33467	Rete Testis	A network of tubules that convey sperm from the seminiferous tubules within the testicles to the efferent ducts.	Rete Testis | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C33819	Tunica Albuginea	The dense whitish fibrous tissue that covers the testis.	Tunica Albuginea | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C33822	Tunica Vaginalis	Serous membrane that covers the testicles.	Tunica Vaginalis | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C4786	Dementia	Loss of intellectual abilities interfering with an individual's social and occupational functions. Causes include Alzheimer's disease, brain injuries, brain tumors, and vascular disorders.	Dementia | comorbidities	C16457	comorbidities
A	C177537	GDC Value Terminology	C48600	Re-Excision	A surgical procedure to remove the remaining abnormal tissues from the body, not completely removed in an earlier attempt.	Re-Excision | treatment_intent_type	C54398	treatment_intent_type
A	C177537	GDC Value Terminology	C53276	Skin of the Extremity	The integumentary covering of the upper and lower extremities.	Skin, Extremities | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C64333	Cyanocobalamin	A cobalt-containing coordination compound generated by intestinal microbes, and a natural water-soluble vitamin of the B-complex family that must combine with Intrinsic Factor for absorption by the intestine. Cyanocobalamin is necessary for hematopoiesis, neural metabolism, DNA and RNA production, and carbohydrate, fat, and protein metabolism. B12 improves iron functions in the metabolic cycle and assists folic acid in choline synthesis. B12 metabolism is interconnected with that of folic acid. Vitamin B12 deficiency causes pernicious anemia, megaloblastic anemia, and neurologic lesions.	Cyanocobalamin | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C7251	Malignant Testicular Neoplasm	A primary or metastatic malignant neoplasm that affects the testis. Representative examples include malignant germ cell tumors, sarcomas, leukemias, and lymphomas.	Testicular Cancer | relationship_primary_diagnosis	C178243	relationship_primary_diagnosis
A	C177537	GDC Value Terminology	C7583	Nevus of Ota	A brown, blue, or gray hamartoma of dermal melanocytes, usually on the skin of the face along the distribution of the ophthalmic and maxillary branches of the trigeminal nerve that is most commonly found in Asian populations and in females and is usually benign. It may also involve the oral or ocular mucosal surfaces, and periosteum.	Nevus of Ota | comorbidities || Nevus of Ota | risk_factors	C16457 || C17103	comorbidities || risk_factors
A	C177537	GDC Value Terminology	C887	Recombinant Thyroid-Stimulating Hormone	A recombinant form of the heterodimeric human anterior pituitary glycoprotein thyroid-stimulating hormone (TSH) with potential use in hormone replacement therapy. Recombinant TSH binds to TSH receptors on thyroid epithelial cells and stimulates TSH-dependent signaling pathways. This stimulates iodine uptake and organification, and induces synthesis and secretion of thyroglobulin (Tg), triiodothyronine (T3), and thyroxine (T4).	rhTSH | pretreatment	C103339	pretreatment
A	C177537	GDC Value Terminology	C94764	Diffuse Intrinsic Pontine Glioma	A glioma that grows diffusely in the pons. It usually affects children and has a poor prognosis.	Diffuse intrinsic pontine glioma, H3 K27M-mutant | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C103817	Hereditary Prostate Carcinoma	Prostate carcinoma that has developed in relatives of patients with a history of prostate carcinoma.	Hereditary Prostate Cancer | comorbidities || Hereditary Prostate Cancer | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C113208	Hypercortisolemia	Abnormally high level of cortisol in the blood.	Cortisol Excess | comorbidities || Cortisol Excess | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C113215	Androgen Excess	Excessive secretion of androgens from the adrenal glands or gonads. Clinical manifestations may include virilization.	Androgen Excess | comorbidities || Androgen Excess | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C113344	Hyperestrogenism	Abnormally high level of estrogen.	Estrogen Excess | comorbidities || Estrogen Excess | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C113444	Roducitabine	An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, roducitabine is taken up by cells through a carrier-mediated transporter, phosphorylated by uridine cytidine kinase (UCK) and then further phosphorylated to its diphosphate (RX-DP) and triphosphate forms (RX-TP). The triphosphate form is incorporated into RNA and inhibits RNA synthesis. The diphosphate RX-DP is reduced by ribonucleotide reductase (RR) to dRX-DP; its triphosphate form (dRX-TP) is incorporated into DNA. In addition, roducitabine also inhibits DNA methyltransferase 1 (DNMT1). This eventually leads to cell cycle arrest and the induction of apoptosis. UCK is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway.	Cytidine Analog RX-3117 | therapeutic_agents || Roducitabine | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C114476	Allergic Reaction	An immune response that occurs following re-exposure to an innocuous antigen, and that requires the presence of existing antibodies against that antigen. This response involves the binding of IgE to mast cells, and may worsen with repeated exposures.	Allergies | comorbidities || Allergies | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C118443	Atigotatug	A monoclonal antibody directed against the ganglioside fucosyl-GM1, with potential antineoplastic and immunomodulating activities. Upon administration, atigotatug binds to fucosyl-GM1 on cancer cells and may activate both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against the bound tumor cells. This may inhibit the proliferation of GM1-expressing tumor cells. Fucosyl-GM1, a sphingolipid monosialoganglioside and tumor associated antigen (TAA), is overexpressed on the surface of many cancer cells while its expression is minimal or non-existent in normal tissues.	Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C118573	Varegacestat	An orally bioavailable, gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon administration, varegacestat binds to GS and blocks the proteolytic cleavage and release of the Notch intracellular domain (NICD), which would normally follow ligand binding to the extracellular domain of the Notch receptor. This prevents both the subsequent translocation of NICD to the nucleus to form a transcription factor complex and the expression of Notch-regulated genes. This results in the induction of apoptosis and the inhibition of growth of tumor cells that overexpress Notch. Overexpression of the Notch signaling pathway plays an important role in tumor cell proliferation and survival. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains and leads to their activation.	GS/pan-Notch Inhibitor BMS-986115 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C120037	Selective Estrogen Receptor Degrader GDC-0927	An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD GDC-0927 specifically binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.	Selective Estrogen Receptor Degrader SRN-927 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C120083	Hereditary Nonpolyposis Colorectal Cancer Syndrome	An inherited syndrome characterized by the development of several cancers, particularly colon and rectal cancers.  It includes Lynch syndrome which is associated with germline mutations in DNA mismatch-repair genes and familial colorectal cancer type X which is characterized by the absence of germline mutations in DNA mismatch-repair genes.	Hereditary Non-Polyposis Colon Cancer | risk_factors || Hereditary Non-polyposis Colon Cancer | comorbidities	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C120861	Adenosis	Any disease or disorder of a gland, characterized by abnormal development or enlargement of the gland.	Adenosis (Atypical Adenomatous Hyperplasia) | comorbidities || Adenosis (Atypical Adenomatous Hyperplasia) | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C121628	Altered Mental Status	A change to an individual's judgment, orientation (to place, time, and self), intellectual functioning, or mood from their baseline.	Altered Mental Status | comorbidities || Altered Mental Status | first_symptom_prior_to_diagnosis || Altered Mental Status | risk_factors	C157233 || C16457 || C17103	first_symptom_prior_to_diagnosis || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C12295	Skin of the Trunk	The skin or integument surrounding the trunk of the body.	Skin of trunk | progression_or_recurrence_anatomic_site || Skin of trunk | site_of_resection_or_biopsy || Skin of trunk | tissue_or_organ_of_origin || Skin, Trunk | sites_of_involvement || Skin, trunk, local | treatment_anatomic_sites	C156421 || C156422 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_sites
C	C177537	GDC Value Terminology	C12298	Retroperitoneum	The back of the abdomen where the kidneys lie and the great blood vessels run.	Retroperitoneal | lymph_node_dissection_site || Retroperitoneum | biospecimen_anatomic_site || Retroperitoneum | progression_or_recurrence_anatomic_site || Retroperitoneum | site_of_resection_or_biopsy || Retroperitoneum | sites_of_involvement || Retroperitoneum | tissue_or_organ_of_origin || Retroperitoneum | treatment_anatomic_sites	C156421 || C156422 || C171435 || C173263 || C177570 || C198458 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || lymph_node_dissection_method || treatment_anatomic_sites
C	C177537	GDC Value Terminology	C123036	Tubulointerstitial Disease	Disease affecting the renal tubules and interstitium of the kidney.	Tubulointerstitial Disease | comorbidities || Tubulointerstitial Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C12311	Cervix Uteri	The lower part of the uterus occupying the region between the isthmus of the uterus and the vagina. It is divided into supravaginal and vaginal portions.	Cervix | biospecimen_anatomic_site || Cervix | sites_of_involvement || Cervix | treatment_anatomic_sites || Cervix Uteri | imaging_anatomic_site || Cervix Uteri | margins_involved_site || Cervix uteri | primary_site || Cervix uteri | progression_or_recurrence_anatomic_site || Cervix uteri | site_of_resection_or_biopsy || Cervix uteri | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177569 || C177570 || C182312 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || margins_involved_site || progression_or_recurrence_anatomic_site || imaging_anatomic_site || treatment_anatomic_sites
C	C177537	GDC Value Terminology	C12326	Undescended Testes	The failure of one or both testes of a male fetus to descend from the abdomen into the scrotum during the late part of pregnancy. If not surgically corrected in early childhood, males may be at increased risk for testicular cancer later in life.	Undescended Testis | comorbidities || Undescended Testis | risk_factors || Undescended testis | progression_or_recurrence_anatomic_site || Undescended testis | site_of_resection_or_biopsy || Undescended testis | tissue_or_organ_of_origin	C156421 || C156422 || C16457 || C17103 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || comorbidities || risk_factors || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C123276	BK Virus Infection	An infection caused by the BK virus. It usually causes an asymptomatic infection, except in immunocompromised individuals where it may cause nephropathy or hemorrhagic cystitis.	BK Virus | comorbidities || BK Virus | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C12329	Spermatic Cord	A tube-like structure composed of the vas deferens and surrounding tissue layers, that runs from the abdomen to each of the testicles.	Spermatic Cord | sites_of_involvement || Spermatic cord | progression_or_recurrence_anatomic_site || Spermatic cord | site_of_resection_or_biopsy || Spermatic cord | tissue_or_organ_of_origin	C156421 || C156422 || C173263 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12344	Choroid	A blood vessel-containing membrane of the eye that lies between the retina and the sclera.	Choroid | progression_or_recurrence_anatomic_site || Choroid | site_of_resection_or_biopsy || Choroid | tissue_or_organ_of_origin || Eye, Choroid | sites_of_involvement	C156421 || C156422 || C173263 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12345	Ciliary Body	Tissue located behind the iris and composed of muscle and epithelium. Its functions include the production of aqueous humor and changing the shape of the crystalline lens.	Ciliary body | progression_or_recurrence_anatomic_site || Ciliary body | site_of_resection_or_biopsy || Ciliary body | tissue_or_organ_of_origin || Eye, Ciliary Body | sites_of_involvement	C156421 || C156422 || C173263 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12360	Intra-Abdominal Lymph Node	Any lymph node within the abdomen.	Intra-Abdominal, NOS | lymph_node_involved_site || Intra-abdominal lymph nodes | progression_or_recurrence_anatomic_site || Intra-abdominal lymph nodes | site_of_resection_or_biopsy || Intra-abdominal lymph nodes | tissue_or_organ_of_origin	C156421 || C156422 || C177570 || C198127	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site || lymph_node_dissection_site
C	C177537	GDC Value Terminology	C123923	Abipapogene Suvaplasmid	A therapeutic DNA vaccine composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), the second is a dimerization entity and the third part encodes a protein that specifically binds to antigen presenting cells (APCs), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration, abipapogene suvaplasmid expresses HPV16 E6/7 and a protein that targets receptors on APCs. Upon binding to APCs and subsequent internalization, the APCs mature and the HPV16 E6/7 antigenic protein is presented by the APCs. This attracts and stimulates B-lymphocytes, CD4-positive T-lymphocytes and elicits a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV16-associated E6 and E7 oncoproteins, which result in tumor cell lysis. HPV16 E6/7, a viral antigen, plays a key role in the development of certain types of cancer.	DNA Vaccine VB10.16 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C12441	Brain Stem	Three sections, the midbrain, pons and medulla oblongata, that are located at the base of the brain. The brain stem regulates the central nervous system, and is vital as a conduit for motor and sensory innervations.	Brain Stem | treatment_anatomic_sites || Brain stem | progression_or_recurrence_anatomic_site || Brain stem | site_of_resection_or_biopsy || Brain stem | tissue_or_organ_of_origin || Brain, Brain stem | sites_of_involvement || Brainstem | biospecimen_anatomic_site	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_sites
C	C177537	GDC Value Terminology	C125900	Anti-CA19-9 Monoclonal Antibody BNT321	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the carbohydrate antigen sialyl Lewis A (carbohydrate antigen 19-9; CA19-9), with potential antineoplastic activity. Upon administration, anti-CA19-9 monoclonal antibody BNT321 targets and binds to CA19-9, and kills CA19-9-expressing tumor cells through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). CA19-9 is overexpressed on a number of different tumor cell types, and plays a key role in tumor cell survival and metastasis.	Anti-CA19-9 Monoclonal Antibody 5B1 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C126449	Serous Tubal Intraepithelial Carcinoma	A non-invasive serous carcinoma arising from the fallopian tube.	Serous Tubal Intraepithelial Carcinoma (STIC) | comorbidities || Serous tubal intraepithelial carcinoma | primary_diagnosis || Serous tubal intraepithelial carcinoma (STIC) | risk_factors	C16457 || C17103 || C177621	comorbidities || risk_factors || primary_diagnosis
C	C177537	GDC Value Terminology	C12698	Common Bile Duct	Bile ducts are passageways that carry bile. Two major bile ducts come together into a "trunk"-the common bile duct which empties into the upper part of the small intestine (the part next to the stomach).	Common Bile Duct | biospecimen_anatomic_site || Common Duct | treatment_anatomic_sites	C171435 || C70729	biospecimen_anatomic_site || treatment_anatomic_sites
C	C177537	GDC Value Terminology	C12785	Scrotum	The musculocutaneous pouch that encloses the testicles.	Scrotum | biospecimen_anatomic_site || Scrotum | sites_of_involvement || Scrotum | treatment_anatomic_sites || Scrotum, NOS | progression_or_recurrence_anatomic_site || Scrotum, NOS | site_of_resection_or_biopsy || Scrotum, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_sites
C	C177537	GDC Value Terminology	C128829	HHV6 Infection	An infection that is caused by human herpesvirus-6.	Human Herpesvirus-6 (HHV-6) | comorbidities || Human Herpesvirus-6 (HHV-6) | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C129314	Vilzemetkib	An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration vilzemetkib targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.	c-Met Inhibitor AL2846 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C131437	Nodular Goiter	Goiter characterized by discrete tissue mass(es) that may or may not produce thyroid hormones.	Thyroid Nodular Hyperplasia | comorbidities || Thyroid Nodular Hyperplasia | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C132166	Inavolisib	An orally available inhibitor of phosphatidylinositol 3-kinase (PI3K), with potential antineoplastic activity. Upon administration, inavolisib binds to and inhibits various members of the PI3K family, including activating mutations in the catalytic alpha isoform PIK3CA. PI3K inhibition prevents the activation of the PI3K-mediated signaling pathway and results in the inhibition of growth and survival of PI3K-overexpressing tumor cells. Dysregulation of the PI3K signaling pathway is frequently associated with tumorigenesis and tumor resistance to a variety of antineoplastic agents and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is frequently mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.	PI3K Inhibitor GDC0077 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C136779	Anti-RNF43 Antibody-drug Conjugate SC-006	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) ring finger protein 43 (RNF43), linked to a DNA crosslinking pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-RNF43 ADC SC-006 targets and binds to RNF43 expressed on tumor cells. Upon binding and internalization, the cytotoxic PBD moiety is released and forms highly cytotoxic DNA interstrand cross-links, thereby blocking cell division and killing RNF43-expressing cancer cells. RNF43, a single-span transmembrane E3 ubiquitin ligase, is overexpressed by certain tumor cell types and a negative regulator of the Wnt signaling pathway.	Antibody-drug Conjugate SC-006 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C137998	Smokeless Tobacco Use	Use of smokeless tobacco in any form, e.g., chewing or sniffing.	Tobacco, Smokeless | comorbidities || Tobacco, Smokeless | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C139578	R0	No detectable presence of residual tumor after treatment	R0 | residual_disease || R0 | residual_tumor	C4809	residual_disease || residual_tumor
C	C177537	GDC Value Terminology	C139579	R1	Presence of microscopic residual tumor after treatment.	R1 | residual_disease || R1 | residual_tumor	C4809	residual_disease || residual_tumor
C	C177537	GDC Value Terminology	C139580	R2	Presence of macroscopic residual tumor after treatment.	R2 | residual_disease || R2 | residual_tumor	C4809	residual_disease || residual_tumor
C	C177537	GDC Value Terminology	C139581	RX	Presence of residual tumor after treatment cannot be assessed.	RX | residual_disease || RX | residual_tumor	C4809	residual_disease || residual_tumor
C	C177537	GDC Value Terminology	C1450	Platinum Compound	A chemotherapy compound that contains a platinum atom. Platinum compounds do not contain alkyl groups but do cause DNA crosslinks and adducts similar to alkylating agents. DNA crosslinks and adducts ultimately lead to the induction of apoptosis.	Platinum | drug_category || Platinum Compound | therapeutic_agents	C188388 || C1909	drug_category || therapeutic_agents
C	C177537	GDC Value Terminology	C146813	Intismeran Autogene	An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting twenty tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed, and genetic sequencing is used to identify twenty neoantigen epitopes that may elicit the strongest immune response in the patient. The sequences encoding the twenty patient-specific epitopes are transcribed and loaded onto a single mRNA molecule. Upon administration, intismeran autogene is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens.	mRNA-based Personalized Cancer Vaccine mRNA-4157 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C150123	Biomarker Positive Malignant Neoplasm	A finding indicating the presence of a biomarker in a tumor sample from a patient with a malignant neoplasm.	Positive Biomarker(s) | evidence_of_progression_type || Positive Biomarker(s) | evidence_of_recurrence_type	C177577 || C198095	evidence_of_recurrence_type || evidence_of_progression_type
C	C177537	GDC Value Terminology	C150383	Fanregratinib	An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Upon administration, fanregratinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs) upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.	FGFR1/2/3 Inhibitor HMPL-453 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C1520	Teloxantrone	An anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis.	Teloxantrone | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C15256	Hysterectomy	A surgical procedure to remove the uterine body (partial hysterectomy) or the uterine body and cervix (total hysterectomy).	Hysterectomy NOS | method_of_sample_procurement || Hysterectomy, NOS | hysterectomy_type || Hysterectomy, NOS | treatment_type	C15256 || C25218 || C70700	hysterectomy_type || treatment_type || method_of_sample_procurement
C	C177537	GDC Value Terminology	C15288	Orchiectomy	Surgical removal of one or both testicles.	Orchiectomy | method_of_diagnosis || Orchiectomy | method_of_sample_procurement || Testis Removed | undescended_testis_corrected_method	C177576 || C182101 || C70700	method_of_diagnosis || undescended_testis_corrected_method || method_of_sample_procurement
C	C177537	GDC Value Terminology	C15289	Organ Transplantation	The transfer of an organ, organ part, or tissue from one body to another, for the purpose of replacing the recipient's damaged or failing organ with a working one from the donor. Donors can be living, or cadaveric (dead).	Organ Transplant (Site) | risk_factors || Organ Transplantation | treatment_type || Organ transplant (site) | comorbidities	C16457 || C17103 || C25218	comorbidities || risk_factors || treatment_type
C	C177537	GDC Value Terminology	C153159	Actinium Ac 225 Rosopatamab Tetraxetan	A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against prostate specific membrane antigen (PSMA) labeled with the alpha particle-emitting radioisotope actinium Ac-225, with potential antineoplastic activity. Upon administration, actinium Ac 225 rosopatamab tetraxetan binds to the extracellular domain of PSMA with high affinity, thereby delivering alpha radiation to PSMA expressing cells. PSMA, a type II membrane protein expressed in all types of prostatic tissues, is often overexpressed in tumor cells.	Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C153377	Zemirciclib	A selective, short-acting inhibitor of the serine/threonine cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF-b; PTEFb), with potential antineoplastic activity. Upon intravenous administration, zemirciclib binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins. This induces cell cycle arrest and apoptosis, and leads to a reduction in tumor cell proliferation. CDK9 regulates elongation of transcription through phosphorylation of RNA polymerase II at serine 2 (p-Ser2-RNAPII). It is upregulated in various tumor cell types and plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.	CDK9 Inhibitor AZD4573 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C154675	Ribociclib/Letrozole	An orally available co-packaged agent combination of the succinate salt form of ribociclib, a cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6, and letrozole, a nonsteroidal inhibitor of estrogen synthesis, with antineoplastic activity. Upon oral administration, ribociclib specifically inhibits CDK4 and CDK6, thereby inhibiting retinoblastoma (Rb) phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent cancer cells.	Ribociclib/Letrozole | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C155871	Herpes Simplex Virus Infection	An infection that is caused by herpes simplex virus.	Herpes | comorbidities || Herpes | risk_factors || Herpes Simplex Virus | aids_risk_factors || Herpes Simplex Virus | risk_factors	C16457 || C17103 || C177623	comorbidities || risk_factors || aids_risk_factors
C	C177537	GDC Value Terminology	C156076	Autoimmune Atrophic Chronic Gastritis	Chronic atrophic gastritis that is caused by autoimmune destruction of parietal cells in the stomach resulting in hypochlorhydria and decreased production of intrinsic factor.	Autoimmune Atrophic Chronic Gastritis | comorbidities || Autoimmune Atrophic Chronic Gastritis | risk_factors || Autoimmune atrophic chronic gastritis | additional_pathology_findings	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C156083	High Grade Dysplasia	A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be high.	Dysplasia; high grade | additional_pathology_findings || High Grade | dysplasia_degree || High Grade Dysplasia | comorbidities || High Grade Dysplasia | esophageal_columnar_dysplasia_degree || High Grade Dysplasia | risk_factors	C158809 || C16457 || C17103 || C177578 || C177641	additional_pathology_findings || comorbidities || risk_factors || dysplasia_degree || esophageal_columnar_dysplasia_degree
C	C177537	GDC Value Terminology	C156084	Low Grade Dysplasia	A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be low.	Dysplasia; low grade | additional_pathology_findings || Low Grade | dysplasia_degree || Low Grade Dysplasia | comorbidities || Low Grade Dysplasia | esophageal_columnar_dysplasia_degree || Low Grade Dysplasia | risk_factors	C158809 || C16457 || C17103 || C177578 || C177641	additional_pathology_findings || comorbidities || risk_factors || dysplasia_degree || esophageal_columnar_dysplasia_degree
C	C177537	GDC Value Terminology	C156464	Succinate Dehydrogenase-Deficient Renal Cell Carcinoma	A very rare renal cell carcinoma that usually affects young adults. It is characterized by mutations in one of the four subunits of the SDH complex (SDHA, SDHB, SDHC, or SDHD gene). Most frequently, the mutations occur in the SDHB subunit. It has a relatively good prognosis.	Succinate Dehydrogenase-Deficient Renal Cell Carcinoma | comorbidities || Succinate Dehydrogenase-Deficient Renal Cell Carcinoma | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C156743	Mevrometostat	An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, mevrometostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.	EZH2 Inhibitor PF-06821497 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C156767	Basal Cell Carcinoma	A carcinoma involving the basal cells.	8090/3 | morphology || Basal Cell Cancer | relationship_primary_diagnosis || Basal Cell Carcinoma | comorbidities || Basal Cell Carcinoma | risk_factors || Basal cell carcinoma, NOS | primary_diagnosis	C16457 || C17103 || C176985 || C177621 || C178243	comorbidities || risk_factors || morphology || primary_diagnosis || relationship_primary_diagnosis
C	C177537	GDC Value Terminology	C156813	Initial Diagnosis	The first diagnosis of the individual's condition.	Initial Diagnosis | initial_disease_status || Initial Diagnosis | timepoint_category	C177616 || C198201	initial_disease_status || timepoint_category
C	C177537	GDC Value Terminology	C156925	Lutadenovec Autogene	A personalized cancer vaccine comprised of a chimpanzee adenovirus vector (ChAdV) encoding twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of lutadenovec autogene, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA vaccine GRT-C901 is followed by monthly boosting with a self-amplifying mRNA (SAM) boosting vaccine that encodes the same 20 target TSNAs. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.	Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C156926	Sapecmeran Autogene	An mRNA-based, personalized cancer vaccine consisting of a self-amplifying mRNA (SAM), formulated in a lipid nanoparticle (LNP), targeting twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of sapecmeran autogene, the mRNA is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of APCs. This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. mRNA-based TSNA boosting vaccine is administered after a single dose of the adenoviral tumor-specific neoantigen priming vaccine GRT-C901.  The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.	mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C157257	Mipletamig	An immunoglobulin Fc-modified bispecific monoclonal antibody against the tumor-associated antigen (TAA) CD123 and the human T-cell surface antigen CD3 bispecific monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Upon administration, mipletamig simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody. Compared to some other CD123 x CD3 targeting bispecific antibodies, mipletamig causes less cytokine release upon T-cell stimulation.	Anti-CD123/CD3 Bispecific Antibody APVO436 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C157424	Visual Change	An alteration in the visual system of an individual.	Vision Changes | comorbidities || Vision Changes | risk_factors || Visual Changes | first_symptom_prior_to_diagnosis	C157233 || C16457 || C17103	first_symptom_prior_to_diagnosis || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C157429	Sensory Change	An alteration in the perceptual senses an individual.	Sensory Changes | comorbidities || Sensory Changes | first_symptom_prior_to_diagnosis || Sensory Changes | risk_factors	C157233 || C16457 || C17103	first_symptom_prior_to_diagnosis || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C157433	Motor / Movement Change	An alteration in the motor/movement of an individual.	Motor / Movement Change | comorbidities || Motor / Movement Change | risk_factors || Motor or Movement Changes | first_symptom_prior_to_diagnosis	C157233 || C16457 || C17103	first_symptom_prior_to_diagnosis || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C158623	Greater Than or Equal to Four	A response indicating that the reported result, quantity or score is greater than or equal to four.	4+ | number_of_pregnancies	C106551	number_of_pregnancies
C	C177537	GDC Value Terminology	C158742	Zeprumetostat	An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, zeprumetostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.	EZH2 Inhibitor SHR2554 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158780	Biopsy with Histologic Confirmation	A biopsy with microscopic confirmation.	Biopsy with Histologic Confirmation | evidence_of_progression_type || Biopsy with Histologic Confirmation | evidence_of_recurrence_type || Histologic Confirmation | evidence_of_progression_type || Histologic Confirmation | evidence_of_recurrence_type	C177577 || C198095	evidence_of_recurrence_type || evidence_of_progression_type
C	C177537	GDC Value Terminology	C160203	Nuvisertib	An orally available, second-generation and selective ATP-competitive inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, nuvisertib selectively binds to and prevents the activation of the PIM kinases. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIM. PIMs, constitutively active proto-oncogenic serine/threonine kinases, are upregulated in various types of cancers and play key roles in tumor cell proliferation and survival.	PIM Kinase Inhibitor TP-3654 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C162188	Clonal Hematopoiesis	Cellular proliferation of hematopoietic cells where a substantial proportion of the cells is derived from a single hematopoietic stem cell lineage.	Clonal Hematopoiesis | comorbidities || Clonal Hematopoiesis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C162693	Eltivutabart	A fully human monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1) with potential immunomodulating and antineoplastic activities. Upon administration, eltivutabart specifically binds to the CD39 antigen, which may inhibit both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy; blocking its action may promote the stimulation of dendritic and other myeloid-derived cells that are necessary for both innate and adaptive immunity.	Anti-CD39 Monoclonal Antibody TTX-030 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C164213	Recurrent Pyogenic Cholangitis	A recurrent form of cholangitis that is characterized by intrabiliary pigment stone formation, biliary tree stricture and obstruction, and recurrent bouts of cholangitis. There is an association with biliary parasitosis, but evidence supporting these infections in the pathogenesis of recurrent pyogenic cholangitis is inconclusive. The most common causes of death are sepsis, liver failure, or complications from cirrhosis. Patients are also at increased risk of cholangiocarcinoma.	Recurrent Pyogenic Cholangitis | comorbidities || Recurrent Pyogenic Cholangitis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C165199	Fovinaciclib	An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, fovinaciclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1/S transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play key roles in the regulation of both cell cycle progression from the G1-phase into the S-phase and cell proliferation.	CDK4/6 Inhibitor FCN-437 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C165779	Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715	A preparation of allogeneic, 'off-the-shelf' (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a monoclonal antibody specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain (TRAC) and CD52 genes are deleted from the CAR T-cells. Upon administration, nendocabtagene onogedleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. Deletion of the CD52 gene makes the modified donor T-cells resistant to an anti-CD52 monoclonal antibody treatment, that is used during lymphodepletion. The knockout of TRAC eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. The donor-derived, gene-edited CAR T cells have reduced production times and have increased availability when compared to autologous CAR-T cells, which use the patient's own cells and are produced on an individual basis. In addition, if nendocabtagene onogedleucel cause unacceptable side effects, the incorporated CD20-based off-switch permits selective depletion of the ALLO-715 cells when the anti-CD20 monoclonal antibody rituximab is administered.	Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C166409	Sacituzumab Tirumotecan	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated, via a methyl sulfonyl pyrimidine linker, to the belotecan derivative and topoisomerase I inhibitor tirumotecan, with potential antineoplastic activity. Upon administration of sacituzumab tirumotecan, sacituzumab targets and binds to TROP2 expressed on tumor cells. Upon both extracellular pH-sensitive cleavage and intracellular enzymatic cleavage of the linker, tirumotecan is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing TROP2. In addition, the bystander effect induced by sacituzumab tirumotecan further inhibits tumor cell proliferation. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues; its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.	Anti-TROP2 Antibody-drug Conjugate SKB264 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C171138	Bacterial Colonization	The detection of bacteria in or on an anatomic site, medical device or biospecimen.	Colonization, Bacterial | comorbidities || Colonization, Bacterial | risk_factors || Colonization; bacterial | additional_pathology_findings	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C171150	Tumor-Associated Lymphocytosis	Non-neoplastic lymphocytosis associated with the presence of a tumor.	Tumor-Associated Lymphoid Proliferation | comorbidities || Tumor-associated Lymphoid Proliferation | risk_factors || Tumor-associated lymphoid proliferation | additional_pathology_findings	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172111	Bosmolisib	An orally bioavailable inhibitor of phosphoinositide 3-kinase delta (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta) and DNA-dependent protein kinase (DNA-PK), with potential antineoplastic and immunomodulating activities. Upon oral administration, bosmolisib inhibits the activity of both PI3K-delta and DNA-PK. This prevents PI3K-mediated signaling pathways and may lead to the inhibition of cancer cell growth in PI3K-overexpressing tumor cells. Specifically, since PI3K regulates c-myc expression, inhibition of PI3K signaling may lead to a decrease in proliferation of c-myc-expressing tumor cells. Also, by inhibiting the activity of DNA-PK, bosmolisib interferes with the non-homologous end joining (NHEJ) process and prevents the repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity by inhibiting the ability of tumor cells to repair damaged DNA. The PI3K pathway is upregulated in a variety of tumors and plays an important role in regulating cancer cell proliferation, growth, and survival. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy. In addition, bosmolisib is able to decrease Tregs and increase CD8 lymphocytes.	DNA-PK/PI3K-delta Inhibitor BR101801 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C172279	Azerutamig	An engineered molecule based on tri-specific natural killer (NK) cell engager therapies (TriNKET) that is directed against human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential immunostimulating and antineoplastic activities. Upon administration, azerutamig targets and binds to HER2 on tumor cells and simultaneously binds to NK cells, thereby bringing HER2-expressing tumor cells and NK cells together, which stimulates the NK cells and results in the selective NK cell-mediated tumor cell lysis of HER2-expressing tumor cells. The binding of HER2-expressing tumor cells and NK cells may also lead to the activation of T-cells and B-cells, potentiating the immune response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	HER2 Tri-specific Natural Killer Cell Engager DF1001 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C172303	Animal Allergy	An allergic reaction triggered by exposure to animal-associated allergens, includes allergenic factors in venom, saliva and dander.	Allergy, Animal, NOS | comorbidities || Allergy, Animal, NOS | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172304	Food Allergy	An allergic reaction triggered by exposure to allergens found in food; exposure can occur through the skin, respiratory tract or digestive tract.	Allergy, Food, NOS | comorbidities || Allergy, Food, NOS | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172306	Mold or Dust Allergy	An allergic reaction triggered by exposure to airborne allergens expressed by dust mites or molds.	Allergy, Mold or Dust | comorbidities || Allergy, Mold or Dust | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172307	Venomous Ant Bite Allergy	An allergic reaction triggered by exposure to ant venom, usually as a result of being bitten by a fire ant (Solenopsis spp.).	Allergy, Ant | comorbidities || Allergy, Ant | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172308	Bee Venom Allergy	An allergic reaction triggered by being exposed to bee venom following a bee sting.	Allergy, Bee | comorbidities || Allergy, Bee | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172310	Cat Allergy	An allergic reaction triggered by exposure to allergens expressed by cats, includes allergenic factors found in feline saliva and dander.	Allergy, Cat | comorbidities || Allergy, Cat | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172311	Dog Allergy	An allergic reaction triggered by exposure to allergens expressed by dogs, includes allergenic factors found in canine saliva and dander.	Allergy, Dog | comorbidities || Allergy, Dog | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172313	Egg Allergy	An allergic reaction triggered by exposure to foodborne allergens found in eggs.	Allergy, Egg | risk_factors || Allergy, Eggs | comorbidities	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172316	Fruit Allergy	An allergic reaction triggered by exposure to foodborne allergens found in fruit.	Allergy, Fruit | comorbidities || Allergy, Fruit | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172317	Meat Allergy	An allergic reaction triggered by exposure to foodborne allergens found in meat.	Allergy, Meat | comorbidities || Allergy, Meat | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172320	Shellfish Allergy	An allergic reaction triggered by exposure to allergens found in foods containing molluscs, crustaceans or echinoderms.	Allergy, Seafood | comorbidities || Allergy, Seafood | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172321	Wasp Venom Allergy	An allergic reaction triggered by being exposed to wasp venom following a wasp sting.	Allergy, Wasp | comorbidities || Allergy, Wasp | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172382	Luvometinib	An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2, with potential antineoplastic activity. Upon administration, luvometinib selectively binds to and inhibits the activity of MEK1 and MEK2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.	MEK 1/2 Inhibitor FCN-159 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C172639	BAP1 Tumor Predisposition Syndrome	A syndrome caused by germline mutations in the BAP1 gene. It is inherited in an autosomal dominant pattern. Individuals carrying heterozygous BAP1 mutations have an increased risk of developing various tumor types, most commonly BAP1-inactivated nevi/melanocytomas of the skin, uveal and cutaneous melanomas, peritoneal and pleural mesotheliomas, clear cell renal cell carcinoma, and basal cell carcinoma. (WHO 2018)	BAP1 Tumor Predisposition Syndrome | comorbidities || BAP1 Tumor Predisposition Syndrome | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C172746	Obecabtagene Autoleucel	A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19, with immunostimulating and antineoplastic activities. Upon administration, obecabtagene autoleucel target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The CAT-41BBz CAR has a faster off-rate compared with FMC63-41BBz CAR. This may minimize cytokine release and reduce toxicities, and enhance persistence of the CAR T-cells.	Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C172821	Caxmotabart Entudotin	An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting the tumor-associated antigen (TAA) epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), site-specifically conjugated, via a tumor-selective beta-glucuronide linker, to the auristatin analog and potent microtubule inhibitor monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of caxmotabart entudotin, the trastuzumab moiety targets and binds to HER2 expressed on tumor cells. Upon binding, internalization and linker cleavage, MMAF is released. MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Trastuzumab Monomethyl Auristatin F | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173364	Gridegalutamide	An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, gridegalutamide causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).	Androgen Receptor Degrader CC-94676 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C174517	Nefextinib	An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, nefextinib binds to and inhibits both FGFR and FLT3, including FLT3 mutant forms, which results in the inhibition of FGFR/FLT3-mediated signal transduction pathways. This inhibits proliferation in FGFR/FLT3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases, is upregulated in many tumor cell types. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias. They both play key roles in cellular proliferation and survival.	FLT3/FGFR Dual Kinase Inhibitor MAX-40279 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C175049	Zolacabtagene Autoleucel	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, zolacabtagene autoleucel specifically target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors.	Autologous CD19-targeted CAR T Cells CC-97540 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C175251	Tegtociclib	An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, tegtociclib selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are frequently overexpressed in tumor cells. CDK2/cyclin E complex plays an important role in retinoblastoma (Rb) protein phosphorylation and the G1-S phase cell cycle transition. CDK2/cyclin A complex plays an important role in DNA synthesis in S phase and the activation of CDK1/cyclin B for the G2-M phase cell cycle transition.	CDK2 Inhibitor PF-07104091 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C175520	Dairy or Lactose Intolerance Allergy	An allergic reaction triggered by exposure to allergens found in foods containing lactose or other dairy components.	Allergy, Dairy or Lactose | comorbidities || Allergy, Dairy or Lactose | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C175521	Nut Allergy	An allergic reaction triggered by exposure to allergens found in nuts.	Allergy, Nuts | comorbidities || Allergy, Nuts | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C175522	Processed Food Allergy	An allergic reaction triggered by exposure to allergens found in processed foods.	Allergy, Processed Foods | comorbidities || Allergy, Processed Foods | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C17649	Other	Different than the one(s) previously specified or mentioned.	Other | additional_pathology_findings || Other | alcohol_type || Other | ann_arbor_b_symptoms_described || Other | biospecimen_anatomic_site || Other | comorbidities || Other | diabetes_treatment_type || Other | dysplasia_type || Other | embolic_agent || Other | first_event || Other | immunosuppressive_treatment_type || Other | instrument_model || Other | library_selection || Other | margins_involved_site || Other | max_tumor_bulk_site || Other | method_of_diagnosis || Other | method_of_sample_procurement || Other | molecular_analysis_method || Other | occupation_type || Other | platform || Other | reason_treatment_ended || Other | relationship_type || Other | sites_of_involvement || Other | therapeutic_agents || Other | timepoint_category || Other | treatment_anatomic_sites || Other | treatment_type || Other | type_of_tobacco_used || Other | variant_type || other | classification_of_tumor || other | race	C158809 || C16457 || C166276 || C17049 || C171435 || C173263 || C173544 || C174459 || C177569 || C177576 || C177610 || C177629 || C18685 || C188396 || C1909 || C19770 || C198107 || C198201 || C25193 || C25218 || C4086 || C43283 || C45378 || C45902 || C574 || C70700 || C70729 || C83393 || C97229 || C99532	additional_pathology_findings || comorbidities || reason_treatment_ended || race || biospecimen_anatomic_site || sites_of_involvement || variant_type || classification_of_tumor || margins_involved_site || method_of_diagnosis || instrument_model || type_of_tobacco_used || library_selection || max_tumor_bulk_site || therapeutic_agents || molecular_analysis_method || first_event || timepoint_category || occupation_type || treatment_type || dysplasia_type || ann_arbor_b_symptoms_described || platform || alcohol_type || immunosuppressive_treatment_type || method_of_sample_procurement || treatment_anatomic_sites || relationship_type || embolic_agent || diabetes_treatment_type
C	C177537	GDC Value Terminology	C17934	Tobacco Smoking	The act of puffing and/or inhaling smoke from a lit cigarette, cigar, or pipe.	Tobacco, Smoking | comorbidities || Tobacco, Smoking | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C179646	Endosalpingiosis	A rare condition characterized by the replacement of the epithelium of an organ which is not related to fallopian tube with ectopic fallopian tube-type ciliated epithelium.	Endosalpingiosis | additional_pathology_findings || Endosalpingiosis | comorbidities || Endosalpingiosis | risk_factors	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C17998	Unknown	Not known, observed, recorded; or reported as unknown by the data contributor.	Unknown | adapter_content || Unknown | adrenal_hormone || Unknown | adverse_event || Unknown | adverse_event_grade || Unknown | ajcc_clinical_m || Unknown | ajcc_clinical_n || Unknown | ajcc_clinical_stage || Unknown | ajcc_clinical_t || Unknown | ajcc_pathologic_m || Unknown | ajcc_pathologic_n || Unknown | ajcc_pathologic_stage || Unknown | ajcc_pathologic_t || Unknown | ajcc_serum_tumor_markers || Unknown | ajcc_staging_system_edition || Unknown | alcohol_frequency || Unknown | alcohol_history || Unknown | alcohol_intensity || Unknown | alcohol_type || Unknown | anaplasia_present || Unknown | anaplasia_present_type || Unknown | aneuploidy || Unknown | ann_arbor_b_symptoms || Unknown | ann_arbor_b_symptoms_described || Unknown | ann_arbor_clinical_stage || Unknown | ann_arbor_extranodal_involvement || Unknown | ann_arbor_pathologic_stage || Unknown | antigen || Unknown | asbestos_exposure_type || Unknown | barretts_esophagus_goblet_cells_present || Unknown | basic_statistics || Unknown | best_overall_response || Unknown | biospecimen_anatomic_site || Unknown | biospecimen_laterality || Unknown | biospecimen_type || Unknown | bone_marrow_malignant_cells || Unknown | burkitt_lymphoma_clinical_variant || Unknown | calgb_risk_group || Unknown | cancer_detection_method || Unknown | cause_of_death || Unknown | cause_of_death_source || Unknown | cdc_hiv_risk_factors || Unknown | chemical_exposure_type || Unknown | chemo_concurrent_to_radiation || Unknown | child_pugh_classification || Unknown | chipseq_antibody || Unknown | chipseq_target || Unknown | chromosomal_translocation || Unknown | chromosome || Unknown | chromosome_arm || Unknown | clark_level || Unknown | classification_of_tumor || Unknown | clonality || Unknown | cog_liver_stage || Unknown | cog_neuroblastoma_risk_group || Unknown | cog_renal_stage || Unknown | cog_rhabdomyosarcoma_risk_group || Unknown | columnar_mucosa_present || Unknown | comorbidities || Unknown | comorbidity_method_of_diagnosis || Unknown | consistent_pathology_review || Unknown | contiguous_organ_invaded || Unknown | country_of_birth || Unknown | country_of_residence_at_enrollment || Unknown | diabetes_treatment_type || Unknown | diagnosis_pathologically_confirmed || Unknown | disease_response || Unknown | disease_type || Unknown | distance_normal_to_tumor || Unknown | double_expressor_lymphoma || Unknown | double_hit_lymphoma || Unknown | drug_category || Unknown | dysplasia_degree || Unknown | dysplasia_type || Unknown | ecog_performance_status || Unknown | education_level || Unknown | eln_risk_classification || Unknown | embolic_agent || Unknown | enneking_msts_grade || Unknown | enneking_msts_metastasis || Unknown | enneking_msts_stage || Unknown | enneking_msts_tumor_site || Unknown | ensat_clinical_m || Unknown | ensat_pathologic_n || Unknown | ensat_pathologic_stage || Unknown | ensat_pathologic_t || Unknown | environmental_tobacco_smoke_exposure || Unknown | epithelioid_cell_percent_range || Unknown | esophageal_columnar_dysplasia_degree || Unknown | esophageal_columnar_metaplasia_present || Unknown | ethnicity || Unknown | evidence_of_progression_type || Unknown | evidence_of_recurrence_type || Unknown | exposure_duration || Unknown | exposure_source || Unknown | exposure_type || Unknown | extracapsular_extension || Unknown | extracapsular_extension_present || Unknown | extranodal_extension || Unknown | extraocular_nodule_size || Unknown | extrascleral_extension_present || Unknown | extrathyroid_extension || Unknown | eye_color || Unknown | figo_stage || Unknown | first_event || Unknown | first_symptom_prior_to_diagnosis || Unknown | fragmentation_enzyme || Unknown | gastric_esophageal_junction_involvement || Unknown | gene_symbol || Unknown | gleason_grade_group || Unknown | gleason_grade_tertiary || Unknown | goblet_cells_columnar_mucosa_present || Unknown | haart_treatment_indicator || Unknown | hepatitis_sustained_virological_response || Unknown | histologic_progression || Unknown | histologic_progression_type || Unknown | histone_family || Unknown | histone_variant || Unknown | history_of_tumor || Unknown | history_of_tumor_type || Unknown | hormonal_contraceptive_type || Unknown | hormonal_contraceptive_use || Unknown | hormonal_replacement_therapy_status || Unknown | hormone_replacement_therapy_type || Unknown | hpv_strain || Unknown | hysterectomy_margins_involved || Unknown | hysterectomy_type || Unknown | igcccg_stage || Unknown | imaging_anatomic_site || Unknown | imaging_findings || Unknown | imaging_result || Unknown | imaging_type || Unknown | immunosuppressive_treatment_type || Unknown | initial_disease_status || Unknown | inpc_grade || Unknown | inpc_histologic_group || Unknown | inrg_stage || Unknown | inss_stage || Unknown | instrument_model || Unknown | international_prognostic_index || Unknown | intratubular_germ_cell_neoplasia_present || Unknown | irs_group || Unknown | irs_stage || Unknown | ishak_fibrosis_score || Unknown | iss_stage || Unknown | karnofsky_performance_status || Unknown | kmer_content || Unknown | laboratory_test || Unknown | largest_extrapelvic_peritoneal_focus || Unknown | laterality || Unknown | lost_to_followup || Unknown | lymph_node_dissection_site || Unknown | lymph_node_involved_site || Unknown | lymph_node_involvement || Unknown | lymph_nodes_removed || Unknown | lymphatic_invasion_present || Unknown | margin_status || Unknown | margins_involved_site || Unknown | marital_status || Unknown | masaoka_stage || Unknown | measurement_type || Unknown | measurement_unit || Unknown | medulloblastoma_molecular_classification || Unknown | melanoma_known_primary || Unknown | menopause_status || Unknown | metaplasia_present || Unknown | metastasis_at_diagnosis || Unknown | method_of_diagnosis || Unknown | method_of_sample_procurement || Unknown | micrometastasis_present || Unknown | micropapillary_features || Unknown | mismatch_repair_mutation || Unknown | mitosis_karyorrhexis_index || Unknown | molecular_analysis_method || Unknown | molecular_consequence || Unknown | morphologic_architectural_pattern || Unknown | morphology || Unknown | mutation_codon || Unknown | necrosis_present || Unknown | non_nodal_regional_disease || Unknown | non_nodal_tumor_deposits || Unknown | nononcologic_therapeutic_agents || Unknown | normal_tumor_genotype_snp_match || Unknown | number_of_pregnancies || Unknown | occupation_type || Unknown | ovarian_specimen_status || Unknown | ovarian_surface_involvement || Unknown | overrepresented_sequences || Unknown | oxygen_use_indicator || Unknown | oxygen_use_type || Unknown | parent_with_radiation_exposure || Unknown | pathogenicity || Unknown | per_base_n_content || Unknown | per_base_sequence_content || Unknown | per_base_sequence_quality || Unknown | per_sequence_gc_content || Unknown | per_sequence_quality_score || Unknown | per_tile_sequence_quality || Unknown | perineural_invasion_present || Unknown | peripancreatic_lymph_nodes_positive || Unknown | peritoneal_fluid_cytological_status || Unknown | peritoneal_washing_results || Unknown | ploidy || Unknown | prcc_type || Unknown | pregnancy_outcome || Unknown | pregnant_at_diagnosis || Unknown | premature_at_birth || Unknown | prescribed_dose_units || Unknown | preservation_method || Unknown | pretreatment || Unknown | primary_diagnosis || Unknown | primary_gleason_grade || Unknown | primary_site || Unknown | prior_treatment || Unknown | procedures_performed || Unknown | progression_or_recurrence || Unknown | progression_or_recurrence_anatomic_site || Unknown | progression_or_recurrence_type || Unknown | protocol_identifier || Unknown | race || Unknown | radiosensitizing_agent || Unknown | reason_treatment_ended || Unknown | reason_treatment_not_given || Unknown | reflux_treatment_type || Unknown | relationship_primary_diagnosis || Unknown | relationship_type || Unknown | relative_deceased || Unknown | relative_smoker || Unknown | residual_disease || Unknown | residual_tumor || Unknown | residual_tumor_measurement || Unknown | rhabdoid_present || Unknown | risk_factor_method_of_diagnosis || Unknown | risk_factor_treatment || Unknown | risk_factors || Unknown | sarcomatoid_present || Unknown | satellite_nodule_present || Unknown | scan_tracer_used || Unknown | second_gene_symbol || Unknown | secondary_gleason_grade || Unknown | secondhand_smoke_as_child || Unknown | sequence_duplication_levels || Unknown | sequence_length_distribution || Unknown | site_of_resection_or_biopsy || Unknown | sites_of_involvement || Unknown | smoking_frequency || Unknown | specimen_type || Unknown | spindle_cell_percent_range || Unknown | staining_intensity_scale || Unknown | staining_intensity_value || Unknown | supratentorial_localization || Unknown | synchronous_malignancy || Unknown | target_capture_kit || Unknown | test_analyte_type || Unknown | test_result || Unknown | test_units || Unknown | test_value_range || Unknown | therapeutic_agents || Unknown | therapeutic_levels_achieved || Unknown | therapeutic_target_level || Unknown | time_between_waking_and_first_smoke || Unknown | timepoint_category || Unknown | tissue_or_organ_of_origin || Unknown | tissue_type || Unknown | tobacco_smoking_status || Unknown | transglottic_extension || Unknown | treatment_anatomic_sites || Unknown | treatment_dose_units || Unknown | treatment_effect || Unknown | treatment_effect_indicator || Unknown | treatment_emergent_adverse_event || Unknown | treatment_frequency || Unknown | treatment_intent_type || Unknown | treatment_outcome || Unknown | treatment_type || Unknown | tumor_confined_to_organ_of_origin || Unknown | tumor_depth_descriptor || Unknown | tumor_descriptor || Unknown | tumor_focality || Unknown | tumor_grade || Unknown | tumor_grade_category || Unknown | tumor_infiltrating_lymphocytes || Unknown | tumor_infiltrating_macrophages || Unknown | tumor_regression_grade || Unknown | tumor_shape || Unknown | type_of_smoke_exposure || Unknown | uicc_clinical_m || Unknown | uicc_clinical_n || Unknown | uicc_clinical_stage || Unknown | uicc_clinical_t || Unknown | uicc_pathologic_m || Unknown | uicc_pathologic_n || Unknown | uicc_pathologic_stage || Unknown | uicc_pathologic_t || Unknown | uicc_staging_system_edition || Unknown | ulceration_indicator || Unknown | undescended_testis_corrected || Unknown | undescended_testis_corrected_age_range || Unknown | undescended_testis_corrected_laterality || Unknown | undescended_testis_corrected_method || Unknown | undescended_testis_history || Unknown | undescended_testis_history_laterality || Unknown | variant_origin || Unknown | variant_type || Unknown | vascular_invasion_present || Unknown | vascular_invasion_type || Unknown | viral_hepatitis_serology_tests || Unknown | vital_status || Unknown | weiss_assessment_findings || Unknown | weiss_assessment_score || Unknown | wgs_coverage || Unknown | who_cns_grade || Unknown | who_nte_grade || Unknown | wilms_tumor_histologic_subtype || Unknown | zygosity || unknown | gender || unknown | prior_malignancy || unknown | progression_or_recurrence || unknown | relationship_gender || unknown | relative_with_cancer_history || unknown | treatment_or_therapy || unknown | vital_status	C102562 || C102704 || C103339 || C104014 || C104015 || C104017 || C104018 || C104023 || C104027 || C105721 || C106304 || C106317 || C106541 || C106551 || C111067 || C111073 || C112400 || C121007 || C123560 || C125738 || C125904 || C126378 || C127762 || C127768 || C127772 || C129439 || C13202 || C132299 || C133427 || C13355 || C133706 || C138899 || C139007 || C140258 || C140259 || C140262 || C140266 || C141342 || C142346 || C143151 || C15256 || C154881 || C15599 || C156421 || C156422 || C157103 || C157110 || C157233 || C157410 || C157425 || C157437 || C158874 || C159229 || C159643 || C159824 || C160720 || C160827 || C160837 || C160996 || C16124 || C161320 || C16165 || C162221 || C164057 || C16457 || C164683 || C16515 || C16564 || C166199 || C166229 || C166276 || C16687 || C168796 || C17001 || C17049 || C17103 || C171253 || C17140 || C171435 || C173263 || C173544 || C17357 || C173595 || C17369 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177569 || C177570 || C177571 || C177572 || C177576 || C177577 || C177578 || C177579 || C177583 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177596 || C177597 || C177598 || C177599 || C177600 || C177601 || C177602 || C177603 || C177604 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177613 || C177614 || C177616 || C177619 || C177620 || C177621 || C177622 || C177624 || C177626 || C177627 || C177628 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C17953 || C181720 || C181723 || C182060 || C182097 || C182099 || C182101 || C182102 || C182109 || C182312 || C18304 || C185074 || C185261 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C188000 || C188372 || C188373 || C188388 || C188406 || C188408 || C188409 || C188411 || C188415 || C188429 || C188446 || C188448 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C198091 || C198092 || C198095 || C198101 || C198107 || C198127 || C198131 || C198139 || C198194 || C198195 || C198198 || C198199 || C198200 || C198201 || C198204 || C198206 || C199145 || C200441 || C200442 || C200444 || C200446 || C200469 || C200470 || C200473 || C200474 || C200476 || C200477 || C20118 || C202137 || C202138 || C202139 || C202140 || C202155 || C202157 || C202158 || C202159 || C202160 || C206478 || C206479 || C206480 || C211836 || C211838 || C211839 || C211840 || C211841 || C211842 || C2480 || C25185 || C25188 || C25193 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C2873 || C29878 || C2991 || C33027 || C3420 || C35529 || C35886 || C36037 || C36292 || C38032 || C39694 || C4086 || C41331 || C42578 || C43283 || C45824 || C45902 || C4809 || C48603 || C48604 || C48605 || C49236 || C50995 || C54398 || C574 || C67415 || C70700 || C70713 || C70729 || C81180 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C93711 || C94536 || C94811 || C95149 || C97229 || C97926 || C99532	inpc_grade || reason_treatment_not_given || pretreatment || weiss_assessment_score || weiss_assessment_findings || ensat_pathologic_stage || ensat_pathologic_t || ensat_pathologic_n || ensat_clinical_m || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || number_of_pregnancies || ajcc_serum_tumor_markers || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || double_hit_lymphoma || alcohol_intensity || staining_intensity_value || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || protocol_identifier || inrg_stage || chromosome_arm || mismatch_repair_mutation || double_expressor_lymphoma || iss_stage || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || gleason_grade_group || masaoka_stage || hysterectomy_type || ulceration_indicator || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || exposure_type || hpv_strain || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || eye_color || primary_site || calgb_risk_group || lymph_nodes_removed || lost_to_followup || lymphatic_invasion_present || satellite_nodule_present || extranodal_extension || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || type_of_smoke_exposure || comorbidities || treatment_emergent_adverse_event || fragmentation_enzyme || ethnicity || treatment_dose_units || tumor_descriptor || reason_treatment_ended || histone_family || pathogenicity || ploidy || race || risk_factors || second_gene_symbol || environmental_tobacco_smoke_exposure || biospecimen_anatomic_site || sites_of_involvement || variant_type || gender || gene_symbol || imaging_type || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || margins_involved_site || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || method_of_diagnosis || evidence_of_recurrence_type || dysplasia_degree || country_of_residence_at_enrollment || target_capture_kit || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || necrosis_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || variant_origin || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serology_tests || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || chipseq_antibody || chipseq_target || initial_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || secondhand_smoke_as_child || smoking_frequency || time_between_waking_and_first_smoke || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || education_level || consistent_pathology_review || undescended_testis_corrected_laterality || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || undescended_testis_corrected_method || undescended_testis_history_laterality || adrenal_hormone || imaging_anatomic_site || clonality || history_of_tumor_type || extraocular_nodule_size || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || alcohol_frequency || exposure_source || asbestos_exposure_type || drug_category || uicc_clinical_m || uicc_clinical_n || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_m || uicc_pathologic_n || uicc_pathologic_stage || uicc_pathologic_t || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || cancer_detection_method || chemical_exposure_type || evidence_of_progression_type || extracapsular_extension || first_event || lymph_node_dissection_site || mutation_codon || peritoneal_washing_results || residual_tumor_measurement || risk_factor_method_of_diagnosis || therapeutic_levels_achieved || test_value_range || therapeutic_target_level || timepoint_category || tumor_grade_category || uicc_staging_system_edition || imaging_findings || country_of_birth || contiguous_organ_invaded || measurement_type || melanoma_known_primary || relative_smoker || wgs_coverage || tumor_depth_descriptor || tumor_shape || tumor_infiltrating_lymphocytes || tumor_infiltrating_macrophages || international_prognostic_index || extracapsular_extension_present || extrathyroid_extension || histologic_progression_type || micrometastasis_present || nononcologic_therapeutic_agents || oxygen_use_indicator || oxygen_use_type || radiosensitizing_agent || staining_intensity_scale || prescribed_dose_units || hormonal_replacement_therapy_status || prcc_type || histologic_progression || undescended_testis_corrected_age_range || epithelioid_cell_percent_range || extrascleral_extension_present || intratubular_germ_cell_neoplasia_present || spindle_cell_percent_range || scan_tracer_used || laterality || marital_status || occupation_type || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || aneuploidy || relative_with_cancer_history || disease_type || lymph_node_involved_site || chromosomal_lymph_node_involvement || morphologic_architectural_pattern || tumor_confined_to_organ_of_origin || test_result || treatment_effect || sarcomatoid_present || dysplasia_type || adverse_event || measurement_unit || ann_arbor_b_symptoms_described || zygosity || alcohol_type || residual_disease || residual_tumor || primary_gleason_grade || secondary_gleason_grade || gleason_grade_tertiary || treatment_or_therapy || disease_response || treatment_intent_type || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || specimen_type || treatment_anatomic_sites || relative_deceased || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || adverse_event_grade || best_overall_response || clark_level || ishak_fibrosis_score || embolic_agent || molecular_consequence || diabetes_treatment_type
C	C177537	GDC Value Terminology	C18059	Tobacco Use	Use of tobacco in any form, e.g., smoking, chewing or sniffing.	Tobacco, NOS | comorbidities || Tobacco, NOS | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C184791	Personal History of Renal Failure Requiring Dialysis	An indication that a subject a history of renal failure that required treatment with dialysis.	Renal Failure (Requiring Dialysis) | risk_factors || Renal Failure (Requiring Dialysis) | comorbidities	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C1873	Apomine	A 1,1-bisphosphonate ester with potential antineoplastic and hypocholesterolemic activities. Apomine binds to hydroxyapatite crystals in the bone matrix where it inhibits enzymatic activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for the formation of mevalonate, the precursor of cholesterol. Consequently, shortage of mevalonate impedes the synthesis of downstream isoprenoids that are essential for protein prenylation. This leads to the loss of activity of proteins involved in osteoclast function and cellular proliferation, such as Ras and Rho, leading to an inhibition of cellular proliferation, and induction of osteoclasts apoptosis. In addition, apomine activates the farnesoid X activated receptor (FXR), a member of the nuclear hormone superfamily implicated in cholesterol metabolism and bile acid transport and may play a role in this agent's antineoplastic effect.	Apomine | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C188229	Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor	A usually indolent neuroendocrine neoplasm that almost exclusively arises in the second part of the duodenum. Rare sites of involvement include jejunum, pylorus, appendix, thymus, and lung. It is a triphasic tumor consisting of a mixture of epithelioid neuroendocrine cells, Schwann-like cells, and ganglion cells.	8683/0 | morphology || Gangliocytic paraganglioma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C188353	Staphylococcal Osteomyelitis	Osteomyelitis resulting from an infection with Staphylococcus.	Staph Osteomyelitis | comorbidities || Staph Osteomyelitis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C198986	Mineralocorticoid Excess	A finding indicating that the concentration of mineralocorticoids in a sample is greater than normal values.	Mineralcorticoids Excess | comorbidities || Mineralocorticoids Excess | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C203250	Neuroendocrine Tumor G1	A well-differentiated, low-grade neuroendocrine neoplasm. It arises from multiple sites, including the digestive system, lung, and head and neck.	G1 | who_nte_grade || Neuroendocrine tumor, grade 1 | primary_diagnosis	C177567 || C177621	who_nte_grade || primary_diagnosis
C	C177537	GDC Value Terminology	C25227	High	An elevated level or position or degree; greater than normal in degree or intensity or amount.	High | test_result	C36292	test_result
C	C177537	GDC Value Terminology	C2632	Naxtarubicin	A lipophilic, anthracycline antineoplastic antibiotic.Naxtarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as inhibiting RNA and protein synthesis.  This agent appears to not be a substrate for the p-glycoprotein associated multidrug-resistance (MDR) transporter; therefore, overcoming the resistance pattern seen with other anthracycline compounds.	Annamycin | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C26323	Hematopoietic and Lymphoid Cell Disorder	A non-neoplastic or neoplastic disorder that arises from the hematopoietic and lymphoid cells. Representative examples include disorders that affect the synthesis of hemoglobin, coagulation disorders, leukemias, and lymphomas.	Hematologic Disorder, NOS | comorbidities || Hematologic Disorder, NOS | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C26713	Cataract	Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.)	Cataracts | comorbidities || Cataracts | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C26714	Celiac Disease	An autoimmune genetic disorder with an unknown pattern of inheritance that primarily affects the digestive tract. It is caused by intolerance to dietary gluten. Consumption of gluten protein triggers an immune response which damages small intestinal villi and prevents adequate absorption of nutrients. Clinical signs include abdominal cramping, diarrhea or constipation and weight loss. If untreated, the clinical course may progress to malnutrition, anemia, osteoporosis and an increased risk of intestinal malignancies. However, the prognosis is favorable with successful avoidance of gluten in the diet.	Celiac Disease | comorbidities || Celiac Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C26725	Common Variable Immunodeficiency	A primary immunodeficiency characterized by low levels or absence of all the immunoglobulin classes and lack of B-lymphocytes or plasma cells. It results in recurrent bacterial infections. Complications include autoimmune phenomena and cancer development.	Common Variable Immunodeficiency | comorbidities || Common Variable Immunodeficiency | risk_factors || Common Variable Immunodeficiency (CVID) | comorbidities || Common variable immune deficiency (CVID) | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C26729	Connective Tissue Disorder	A non-neoplastic or neoplastic disorder that affects the connective tissue.	Connective Tissue Disorder | comorbidities || Connective Tissue Disorder | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C26732	Coronary Artery Disease	Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC)	Coronary Artery Disease | comorbidities || Coronary Artery Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C26781	Gastroesophageal Reflux Disease	A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.	GERD | comorbidities || GERD | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C26782	Glaucoma	Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.	Glaucoma | comorbidities || Glaucoma | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C26797	Hyperglycemia	Abnormally high level of glucose in the blood.	Hyperglycemia | comorbidities || Hyperglycemia | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C26869	Pulmonary Fibrosis	Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).	Pulmonary Fibrosis | comorbidities || Pulmonary Fibrosis | risk_factors || Pulmonary interstitial fibrosis | additional_pathology_findings	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C26882	Sialadenitis	An acute or chronic inflammatory process affecting a salivary gland. Signs and symptoms include pain and tenderness in the affected area.	Sialadenitis | additional_pathology_findings || Sialadenitis | comorbidities || Sialadenitis | risk_factors	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C26884	Sleep Apnea	Cessation of breathing for short periods during sleep. It is classified as obstructive, central, or mixed obstructive-central. It can occur at any age but it is more frequent in people over forty. Risk factors include male sex and obesity.	Sleep Apnea | risk_factors || Sleep apnea | comorbidities	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C27006	Interstitial Pneumonia	Inflammation of interstitial lung tissue, usually associated with infection.	Interstitial Pneumonitis or ARDS | risk_factors || Interstitial Pneumontis or ARDS | comorbidities	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C27121	Helicobacter Pylori-Associated Gastritis	Inflammation of the stomach that is associated with Helicobacter Pylori.	Helicobacter Pylori-Associated Gastritis | risk_factors || Helicobacter pylori-Associated Gastritis | comorbidities	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C27153	Lupus Erythematosus	An autoimmune, connective tissue chronic inflammatory disorder affecting the skin, joints, kidneys, lungs, heart, and the peripheral blood cells. It is more commonly seen in women than men. Variants include discoid and systemic lupus erythematosus.	Lupus | comorbidities || Lupus | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C27204	Rheumatologic Disorder	Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.	Rheumatologic Disease | comorbidities || Rheumatologic Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C27252	Enterochromaffin-Like Cell Neuroendocrine Tumor G1	A well-differentiated, low-grade neuroendocrine neoplasm arising from the gastrointestinal tract. It is characterized by the presence of enterochromaffin-like type granules in the neoplastic cells. The mitotic count is less than 2 per 2 mm2 and the Ki-67 index is less than 3%.	8242/1 | morphology || 8242/3 | morphology || ECL cell carcinoid, NOS | primary_diagnosis || ECL cell carcinoid, malignant | primary_diagnosis || Enterochromaffin-like cell carcinoid, NOS | primary_diagnosis || Enterochromaffin-like cell tumor, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C27566	Non-Neoplastic Thyroid Gland Disorder	A non-neoplastic disorder that affects the thyroid gland.  Representative examples include hyperthyroidism, hypothyroidism, thyroiditis, and thyroid gland abscess.	Thyroid Disease, Non-Cancer | comorbidities || Thyroid Disease, Non-Cancer | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C27582	Central Nervous System Infectious Disorder	An infectious process that affects the brain and/or spinal cord. Representative examples include encephalitis, poliomyelitis, arachnoiditis, and meningitis.	CNS Infection | comorbidities || CNS Infection | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C27996	Myocardial Infarction	Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis.	Myocardial Infarction | comorbidities || Myocardial Infarction | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C28244	Birt-Hogg-Dube Syndrome	A rare genetic syndrome with an autosomal dominant pattern of inheritance. It is caused by a mutation in the FLCN gene which encodes the protein folliculin. Clinical signs include multiple benign growths of the skin and lungs that begin to manifest in the second or third decade of life. The clinical course is characterized by the progressive growth of new and existing neoplasms. In those with mutations in both copies of FLCN, the kidneys may also be affected by the growth of benign or malignant neoplasms.	Birt-Hogg-Dube Syndrome | comorbidities || Birt-Hogg-Dube Syndrome | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C2851	Acquired Immunodeficiency Syndrome	A syndrome resulting from the acquired deficiency of cellular immunity caused by the human immunodeficiency virus (HIV). It is characterized by the reduction of the Helper T-lymphocytes in the peripheral blood and the lymph nodes. Symptoms include generalized lymphadenopathy, fever, weight loss, and chronic diarrhea. Patients with AIDS are especially susceptible to opportunistic infections, tuberculosis, candida infections, and cryptococcosis), and the development of malignant neoplasms (usually non-Hodgkin lymphoma and Kaposi sarcoma). The human immunodeficiency virus is transmitted through sexual contact, sharing of contaminated needles, or transfusion of contaminated blood.	HIV/AIDS | comorbidities || HIV/AIDS | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C2852	Adenocarcinoma	A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.	8140/3 | morphology || Adenocarcinoma | comorbidities || Adenocarcinoma | risk_factors || Adenocarcinoma, NOS | primary_diagnosis	C16457 || C17103 || C176985 || C177621	comorbidities || risk_factors || morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C2883	Arthritis	An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.	Arthritis | comorbidities || Arthritis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C2897	Benign Prostatic Hyperplasia	A non-cancerous nodular enlargement of the prostate gland.  It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements.  It is the most common urologic disorder in men, causing blockage of urine flow.	Benign Prostatic Hyperplasia | risk_factors || Benign Prostatic Hyperplasia | comorbidities || Nodular Prostatic Hyperplasia | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C2899	Biliary System Disorder	A non-neoplastic or neoplastic disorder that affects the intrahepatic or extrahepatic bile ducts or the gallbladder. Representative examples of non-neoplastic disorders include cholangitis and cholecystitis. Representative examples of neoplastic disorders include extrahepatic bile duct adenoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.	Biliary Disorder | comorbidities || Biliary Disorder | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C2911	Bronchitis	An acute or chronic inflammatory process affecting the bronchi.	Bronchitis | comorbidities || Bronchitis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C2921	Skin Basal Cell Carcinoma	The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.	8090/3 | morphology || Basal cell epithelioma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C2938	Cerebrovascular Disorder	A disorder resulting from inadequate blood flow in the vessels that supply the brain. Representative examples include cerebrovascular ischemia, cerebral embolism, and cerebral infarction.	Cerebrovascular Disease | comorbidities || Cerebrovascular Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C2951	Cirrhosis	A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.	Cirrhosis | additional_pathology_findings || Cirrhosis, Unknown Etiology | comorbidities || Liver Cirrhosis (Liver Disease) | comorbidities || Liver Cirrhosis (Liver Disease) | risk_factors	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C2965	Crohn Disease	A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.	Crohn's Disease | comorbidities || Crohn's Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C2978	Cyst	A sac-like closed membranous structure that may be empty or contain fluid or amorphous material.	Cyst(s) | additional_pathology_findings || Cyst(s) | comorbidities || Cyst(s) | risk_factors	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C2985	Diabetes Mellitus	A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.	Diabetes, NOS | comorbidities || Diabetes, NOS | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C2986	Type 1 Diabetes Mellitus	A chronic condition characterized by minimal or absent production of insulin by the pancreas.	Diabetes, Type I | comorbidities || Diabetes, Type I | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3014	Endometriosis	The growth of functional endometrial tissue in anatomic sites outside the uterine body. It most often occurs in the pelvic organs.	Endometriosis | additional_pathology_findings || Endometriosis | comorbidities || Endometriosis | risk_factors	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3037	Chronic Fatigue Syndrome	A syndrome of unknown etiology. Chronic fatigue syndrome (CFS) is a clinical diagnosis characterized by an unexplained persistent or relapsing chronic fatigue that is of at least six months' duration, is not the result of ongoing exertion, is not substantially alleviated by rest, and results in substantial reduction of previous levels of occupational, educational, social, or personal activities. Common concurrent symptoms of at least six months duration include impairment of memory or concentration, diffuse pain, sore throat, tender lymph nodes, headaches of a new type, pattern, or severity, and nonrestorative sleep. The etiology of CFS may be viral or immunologic. Neurasthenia and fibromyalgia may represent related disorders. Also known as myalgic encephalomyelitis.	Chronic Fatigue Syndrome | comorbidities || Chronic Fatigue Syndrome | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3076	Cowden Syndrome	An autosomal dominant hereditary syndrome characterized by a variety of hamartomas and neoplasms including verrucous skin lesions, fibromas of the oral cavity, facial trichilemmomas, hamartomatous colonic polyps, thyroid neoplasms, breast cancer, and dysplastic gangliocytomas of the cerebellum.	Cowden Syndrome | comorbidities || Cowden Syndrome | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3079	Heart Disorder	A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.	Heart Disease | comorbidities || Heart Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3080	Congestive Heart Failure	Failure of the heart to pump a sufficient amount of blood to meet the needs of the body tissues, resulting in tissue congestion and edema. Signs and symptoms include shortness of breath, pitting edema, enlarged tender liver, engorged neck veins, and pulmonary rales.	Congestive Heart Failure (CHF) | comorbidities || Congestive Heart Failure (CHF) | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3095	Hepatitis	Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.	Hepatitis, NOS | comorbidities || Hepatitis, NOS | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3101	Genetic Disorder	Genetic diseases are diseases in which inherited genes predispose to increased risk. The genetic disorders associated with cancer often result from an alteration or mutation in a single gene. The diseases range from rare dominant cancer family syndrome to familial tendencies in which low-penetrance genes may interact with other genes or environmental factors to induce cancer. Research may involve clinical, epidemiologic, and laboratory studies of persons, families, and populations at high risk of these disorders.	Inherited Genetic Syndrome, NOS | comorbidities || Inherited Genetic Syndrome, NOS | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3105	Von Hippel Lindau Syndrome	An inherited familial cancer syndrome which is characterized by development of capillary hemangioblastomas of the central nervous system and retina; clear cell renal carcinoma; pheochromocytoma; pancreatic tumors; and inner ear tumors. The syndrome is associated with germline mutations of the VHL tumor suppressor gene, located on chromosome 3p25-26. Symptoms of VHL syndrome may not be apparent until the third decade of life. CNS hemangioblastoma is the most common cause of death, followed by clear cell renal cell carcinoma. --2004	Von Hippel-Lindau Syndrome | comorbidities || Von Hippel-Lindau Syndrome | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3108	HIV Infection	An infection caused by the human immunodeficiency virus.	HIV/AIDS | comorbidities || HIV/AIDS | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3137	Inflammation	A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.	Inflammation | additional_pathology_findings || Inflammation | comorbidities || Inflammation | risk_factors || Inflammation, Hyperkeratosis | risk_factors	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3138	Inflammatory Bowel Disease	A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn's disease, ulcerative colitis, and colitis of indeterminate type.	Inflammatory Bowel Disease | comorbidities || Inflammatory Bowel Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3149	Kidney Disorder	A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).	Renal Disorder, NOS | cause_of_death	C81239	cause_of_death
C	C177537	GDC Value Terminology	C3199	Chronic Obstructive Pulmonary Disease	A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.	COPD | comorbidities || COPD | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3237	Squamous Metaplasia	A morphologic finding indicating the transformation of glandular or transitional epithelial cells to, usually, mature squamous epithelial cells.  Representative examples include squamous metaplasia of bronchial epithelium, cervix, urinary bladder, and prostate gland.	Squamous Metaplasia | comorbidities || Squamous Metaplasia | risk_factors || Squamous metaplasia | additional_pathology_findings	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3247	Myelodysplastic Syndrome	A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)	Myelodysplastic Syndrome | comorbidities || Myelodysplastic Syndrome | risk_factors || Myelodysplastic Syndromes | disease_type || Preleukemia | primary_diagnosis || Preleukemic syndrome | primary_diagnosis	C16457 || C17103 || C177621 || C2991	comorbidities || risk_factors || primary_diagnosis || disease_type
C	C177537	GDC Value Terminology	C3293	Osteoarthritis	A noninflammatory degenerative joint disease occurring chiefly in older persons, characterised by degeneration of the articular cartilage, hypertrophy of bone at the margins and changes in the synovial membrane. It is accompanied by pain and stiffness, particularly after prolonged activity.	Osteoarthritis | comorbidities || Osteoarthritis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3318	Peptic Ulcer	A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.	Peptic Ulcer (Ulcer) | comorbidities || Peptic Ulcer (Ulcer) | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3324	Peutz-Jeghers Syndrome	An inherited condition characterized by generalized hamartomatous multiple polyposis of the intestinal tract. Transmitted in an autosomal dominant fashion, Peutz-Jeghers syndrome consistently involves the jejunum and is associated with melanin spots of the lips, buccal mucosa, and fingers. This syndrome is associated with abnormalities of chromosome 19. Also known as Jeghers-Peutz syndrome and Peutz's syndrome.	Peutz-Jeghers Disease | comorbidities || Peutz-Jeghers Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C333	Calcium Channel Blocker	A pharmaceutical agent that inhibits the movement of calcium across through calcium channels in the cell membrane, preventing or decreasing the amount of calcium able to enter the cell. These drugs are used for their chronotropic, antihypertensive and vasodilatory effects.	Calcium Channel Blockers | comorbidities || Calcium Channel Blockers | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3339	Familial Adenomatous Polyposis	An autosomal dominant disorder, characterized by the presence of multiple adenomas in the colon and rectum. It is caused by a germline mutation in the adenomatous polyposis coli (APC) gene which is located on the long arm of chromosome 5. The adenomas are most often tubular, and they have the tendency to progress to adenocarcinoma. They can occur throughout the colon, but they tend to concentrate in the rectum and sigmoid colon. The colorectal adenomas are detected during endoscopic examination between the age of 10 and 20 years. The adenomas increase in size and numbers with age, and there is usually progression of one or more adenomas to adenocarcinoma. The mean age of development of adenocarcinoma is about 40 years. Signs include rectal bleeding and mucousy diarrhea.	8220/0 | morphology || Adenomatous Polyposis Coli | comorbidities || Adenomatous Polyposis Coli | risk_factors || Adenomatous polyposis coli | primary_diagnosis || Familial Adenomatous Polyposis | comorbidities || Familial Adenomatous Polyposis | risk_factors || Familial polyposis coli | primary_diagnosis	C16457 || C17103 || C176985 || C177621	comorbidities || risk_factors || morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3346	Psoriasis	An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.	Psoriasis | comorbidities || Psoriasis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3353	Acute Respiratory Distress Syndrome	Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.	Interstitial Pneumonitis or ARDS | risk_factors || Interstitial Pneumontis or ARDS | comorbidities	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3424	Tuberous Sclerosis	Hereditary disease characterized by seizures, mental retardation, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.	Tuberous Sclerosis | comorbidities || Tuberous Sclerosis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3446	Primary Immune Thrombocytopenia	Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).	ITP | comorbidities || ITP | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C34650	Gout	A condition characterized by painful swelling of the joints, which is caused by deposition of urate crystals.	Gout | comorbidities || Gout | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C34707	Hyperlipidemia	Elevated levels of lipids in the blood.	Hyperlipidemia | comorbidities || Hyperlipidemia | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C34783	Alcoholic Liver Disease	A disorder caused by damage to the liver parenchyma due to alcohol consumption. It may present with an acute onset or follow a chronic course, leading to cirrhosis.	Alcoholic Liver Disease | comorbidities || Alcoholic Liver Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C35064	Hereditary Hemorrhagic Telangiectasia	An autosomal dominant hereditary disorder caused by mutations in the ACVRL1, ENG, and SMAD4 genes. It is characterized by the presence of telangiectasias in the skin, mucous membranes, lungs, brain, liver, and gastrointestinal tract. It results in hemorrhages from the affected areas.	Hereditary Hemorrhagic Telangiectasia | comorbidities || Hereditary Hemorrhagic Telangiectasia | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C35117	Vascular Disorder	A non-neoplastic or neoplastic disorder affecting the arteries, veins, or lymphatic vessels. Examples include vasculitis, thrombophlebitis, arteriosclerosis, lymphedema, hemangioma, and angiosarcoma.	Vascular Disease | comorbidities || Vascular Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C35136	Peripheral Vascular Disorder	Any disorder affecting blood flow through the veins or arteries outside of the heart.	Peripheral Vascular Disease | comorbidities || Peripheral Vascular Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C35541	Hyperkeratosis	Hypertrophy of the outermost layer of the epidermis. It may be caused by physical or chemical irritants, irradiation, infection, or neoplastic processes.	Hyperkeratosis | additional_pathology_findings || Inflammation, Hyperkeratosis | comorbidities || Inflammation, Hyperkeratosis | risk_factors	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C35605	Glomerular Vascular Disorder	A disorder that is caused by pathologic changes in the glomerular vasculature.	Glomerular Disease | comorbidities || Glomerular Disease | risk_factors || Glomerular disease | additional_pathology_findings	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C36102	Hereditary Ovarian Carcinoma	Ovarian carcinoma that has developed in relatives of patients that have a history of ovarian carcinoma.	Hereditary Ovarian Cancer | comorbidities || Hereditary Ovarian Cancer | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3770	Pancreatic Neuroendocrine Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the islet cells of the pancreas. It is composed of malignant small or large cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.	8150/3 | morphology || Islet cell adenocarcinoma | primary_diagnosis || Islet cell carcinoma | primary_diagnosis || Pancreatic endocrine tumor, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3773	Neuroendocrine Carcinoma	An aggressive carcinoma composed of malignant cells that exhibit neuroendocrine differentiation. It is classified as small cell or large cell neuroendocrine carcinoma.	8246/3 | morphology || Neuroendocrine carcinoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3809	Neuroendocrine Neoplasm	An epithelial neoplasm with neuroendocrine differentiation. This category includes neuroendocrine tumors, neuroendocrine carcinomas, and paragangliomas.	Neuroendocrine Tumor | comorbidities || Neuroendocrine Tumor | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C38342	Pancreatic Intraductal Papillary-Mucinous Neoplasm	A usually slow-growing epithelial neoplasm with ductal differentiation that arises from the exocrine pancreas and grows mostly within the pancreatic ducts. Grossly, it is characterized by the presence of intraductal masses. Morphologically, there is proliferation of mucin-producing cells within the pancreatic ducts, intraductal accumulation of mucin, and a papillary growth pattern. It may be associated with the presence of an invasive carcinoma. It usually occurs in older patients. Signs and symptoms include epigastric pain, weight loss, jaundice, chronic pancreatitis, and diabetes mellitus.	Intraductal Papillary Mucinous Neoplasm | risk_factors || Intraductal Papillary Mucinous Neoplasm | comorbidities	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3915	Small Cell Neuroendocrine Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation composed of malignant small cells.	8041/3 | morphology || 8042/3 | morphology || Oat cell carcinoma | primary_diagnosis || Reserve cell carcinoma | primary_diagnosis || Round cell carcinoma | primary_diagnosis || Small cell carcinoma, NOS | primary_diagnosis || Small cell neuroendocrine carcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C39291	HHV8 Infection	An infectious process caused by the human herpesvirus 8. This infection is associated with Kaposi sarcoma.	Human Herpesvirus-8 (HHV-8) | comorbidities || Human Herpesvirus-8 (HHV-8) | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3954	Gastric Polyp	A polyp that arises from the stomach.  This category includes neoplastic polyps (intestinal-type adenomatous polyps, gastric-type adenomas, and fundic gland polyps), and non-neoplastic polyps (hyperplastic polyps and hamartomatous polyps).	Gastric Polyp(s) | comorbidities || Gastric Polyp(s) | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C39594	Skin Rash	Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful.	Skin Rash | comorbidities || Skin Rash | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C39789	Hereditary Renal Cell Carcinoma	Renal cell carcinoma that has developed in relatives of patients with history of renal cell carcinoma.	Hereditary Renal Cell Carcinoma | comorbidities || Hereditary Renal Cell Carcinoma | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C40182	Uterine Corpus Carcinofibroma	An uncommon malignant neoplasm arising from the uterine corpus. It is characterized by the presence of a malignant epithelial component and a benign mesenchymal (usually fibrous) component.	8934/3 | morphology || Carcinofibroma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4145	Adenocarcinoma in Tubulovillous Adenoma	An adenocarcinoma that arises from a tubulovillous adenoma.	8263/3 | morphology || Adenocarcinoma in tubulovillous adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C43234	Not Reported	Not provided or available.	Not Reported | adapter_content || Not Reported | adrenal_hormone || Not Reported | adverse_event || Not Reported | adverse_event_grade || Not Reported | ajcc_clinical_m || Not Reported | ajcc_clinical_n || Not Reported | ajcc_clinical_stage || Not Reported | ajcc_clinical_t || Not Reported | ajcc_pathologic_m || Not Reported | ajcc_pathologic_n || Not Reported | ajcc_pathologic_stage || Not Reported | ajcc_pathologic_t || Not Reported | ajcc_serum_tumor_markers || Not Reported | ajcc_staging_system_edition || Not Reported | alcohol_frequency || Not Reported | alcohol_history || Not Reported | alcohol_intensity || Not Reported | alcohol_type || Not Reported | anaplasia_present || Not Reported | anaplasia_present_type || Not Reported | aneuploidy || Not Reported | ann_arbor_b_symptoms || Not Reported | ann_arbor_b_symptoms_described || Not Reported | ann_arbor_clinical_stage || Not Reported | ann_arbor_extranodal_involvement || Not Reported | ann_arbor_pathologic_stage || Not Reported | antigen || Not Reported | asbestos_exposure_type || Not Reported | barretts_esophagus_goblet_cells_present || Not Reported | basic_statistics || Not Reported | best_overall_response || Not Reported | biospecimen_anatomic_site || Not Reported | biospecimen_laterality || Not Reported | biospecimen_type || Not Reported | bone_marrow_malignant_cells || Not Reported | burkitt_lymphoma_clinical_variant || Not Reported | calgb_risk_group || Not Reported | cancer_detection_method || Not Reported | cause_of_death || Not Reported | cause_of_death_source || Not Reported | cdc_hiv_risk_factors || Not Reported | chemical_exposure_type || Not Reported | chemo_concurrent_to_radiation || Not Reported | child_pugh_classification || Not Reported | chromosomal_translocation || Not Reported | chromosome || Not Reported | chromosome_arm || Not Reported | clark_level || Not Reported | clinical_trial_indicator || Not Reported | clonality || Not Reported | cog_liver_stage || Not Reported | cog_neuroblastoma_risk_group || Not Reported | cog_renal_stage || Not Reported | cog_rhabdomyosarcoma_risk_group || Not Reported | columnar_mucosa_present || Not Reported | comorbidities || Not Reported | comorbidity_method_of_diagnosis || Not Reported | consistent_pathology_review || Not Reported | contiguous_organ_invaded || Not Reported | country_of_birth || Not Reported | country_of_residence_at_enrollment || Not Reported | diabetes_treatment_type || Not Reported | diagnosis_pathologically_confirmed || Not Reported | disease_response || Not Reported | disease_type || Not Reported | distance_normal_to_tumor || Not Reported | double_expressor_lymphoma || Not Reported | double_hit_lymphoma || Not Reported | drug_category || Not Reported | dysplasia_degree || Not Reported | dysplasia_type || Not Reported | ecog_performance_status || Not Reported | education_level || Not Reported | eln_risk_classification || Not Reported | embolic_agent || Not Reported | enneking_msts_grade || Not Reported | enneking_msts_metastasis || Not Reported | enneking_msts_stage || Not Reported | enneking_msts_tumor_site || Not Reported | ensat_clinical_m || Not Reported | ensat_pathologic_n || Not Reported | ensat_pathologic_stage || Not Reported | ensat_pathologic_t || Not Reported | environmental_tobacco_smoke_exposure || Not Reported | epithelioid_cell_percent_range || Not Reported | esophageal_columnar_dysplasia_degree || Not Reported | esophageal_columnar_metaplasia_present || Not Reported | evidence_of_progression_type || Not Reported | evidence_of_recurrence_type || Not Reported | exposure_duration || Not Reported | exposure_source || Not Reported | exposure_type || Not Reported | extracapsular_extension || Not Reported | extracapsular_extension_present || Not Reported | extranodal_extension || Not Reported | extraocular_nodule_size || Not Reported | extrascleral_extension_present || Not Reported | extrathyroid_extension || Not Reported | eye_color || Not Reported | figo_stage || Not Reported | first_event || Not Reported | first_symptom_prior_to_diagnosis || Not Reported | gastric_esophageal_junction_involvement || Not Reported | gene_symbol || Not Reported | gleason_grade_group || Not Reported | gleason_grade_tertiary || Not Reported | goblet_cells_columnar_mucosa_present || Not Reported | haart_treatment_indicator || Not Reported | hepatitis_sustained_virological_response || Not Reported | histologic_progression || Not Reported | histologic_progression_type || Not Reported | histone_family || Not Reported | histone_variant || Not Reported | history_of_tumor || Not Reported | history_of_tumor_type || Not Reported | hormonal_contraceptive_type || Not Reported | hormonal_contraceptive_use || Not Reported | hormonal_replacement_therapy_status || Not Reported | hormone_replacement_therapy_type || Not Reported | hpv_strain || Not Reported | hysterectomy_margins_involved || Not Reported | hysterectomy_type || Not Reported | igcccg_stage || Not Reported | imaging_anatomic_site || Not Reported | imaging_findings || Not Reported | imaging_result || Not Reported | imaging_type || Not Reported | immunosuppressive_treatment_type || Not Reported | initial_disease_status || Not Reported | inpc_grade || Not Reported | inpc_histologic_group || Not Reported | inrg_stage || Not Reported | inss_stage || Not Reported | instrument_model || Not Reported | international_prognostic_index || Not Reported | intratubular_germ_cell_neoplasia_present || Not Reported | irs_group || Not Reported | irs_stage || Not Reported | ishak_fibrosis_score || Not Reported | iss_stage || Not Reported | karnofsky_performance_status || Not Reported | kmer_content || Not Reported | laboratory_test || Not Reported | largest_extrapelvic_peritoneal_focus || Not Reported | laterality || Not Reported | lymph_node_dissection_site || Not Reported | lymph_node_involved_site || Not Reported | lymph_node_involvement || Not Reported | lymph_nodes_removed || Not Reported | lymphatic_invasion_present || Not Reported | margin_status || Not Reported | margins_involved_site || Not Reported | marital_status || Not Reported | masaoka_stage || Not Reported | measurement_type || Not Reported | measurement_unit || Not Reported | medulloblastoma_molecular_classification || Not Reported | melanoma_known_primary || Not Reported | menopause_status || Not Reported | metaplasia_present || Not Reported | metastasis_at_diagnosis || Not Reported | method_of_diagnosis || Not Reported | method_of_sample_procurement || Not Reported | micrometastasis_present || Not Reported | micropapillary_features || Not Reported | mismatch_repair_mutation || Not Reported | mitosis_karyorrhexis_index || Not Reported | molecular_analysis_method || Not Reported | molecular_consequence || Not Reported | morphologic_architectural_pattern || Not Reported | morphology || Not Reported | mutation_codon || Not Reported | necrosis_present || Not Reported | non_nodal_regional_disease || Not Reported | non_nodal_tumor_deposits || Not Reported | nononcologic_therapeutic_agents || Not Reported | normal_tumor_genotype_snp_match || Not Reported | number_of_pregnancies || Not Reported | occupation_type || Not Reported | ovarian_specimen_status || Not Reported | ovarian_surface_involvement || Not Reported | overrepresented_sequences || Not Reported | oxygen_use_indicator || Not Reported | oxygen_use_type || Not Reported | parent_with_radiation_exposure || Not Reported | pathogenicity || Not Reported | per_base_n_content || Not Reported | per_base_sequence_content || Not Reported | per_base_sequence_quality || Not Reported | per_sequence_gc_content || Not Reported | per_sequence_quality_score || Not Reported | per_tile_sequence_quality || Not Reported | perineural_invasion_present || Not Reported | peripancreatic_lymph_nodes_positive || Not Reported | peritoneal_fluid_cytological_status || Not Reported | peritoneal_washing_results || Not Reported | ploidy || Not Reported | prcc_type || Not Reported | pregnancy_outcome || Not Reported | pregnant_at_diagnosis || Not Reported | premature_at_birth || Not Reported | prescribed_dose_units || Not Reported | preservation_method || Not Reported | pretreatment || Not Reported | primary_diagnosis || Not Reported | primary_gleason_grade || Not Reported | primary_site || Not Reported | prior_treatment || Not Reported | procedures_performed || Not Reported | progression_or_recurrence || Not Reported | progression_or_recurrence_anatomic_site || Not Reported | progression_or_recurrence_type || Not Reported | radiosensitizing_agent || Not Reported | reason_treatment_ended || Not Reported | reason_treatment_not_given || Not Reported | reflux_treatment_type || Not Reported | relationship_primary_diagnosis || Not Reported | relationship_type || Not Reported | relative_deceased || Not Reported | relative_smoker || Not Reported | residual_disease || Not Reported | residual_tumor || Not Reported | residual_tumor_measurement || Not Reported | rhabdoid_present || Not Reported | risk_factor_method_of_diagnosis || Not Reported | risk_factor_treatment || Not Reported | risk_factors || Not Reported | route_of_administration || Not Reported | sarcomatoid_present || Not Reported | satellite_nodule_present || Not Reported | scan_tracer_used || Not Reported | second_gene_symbol || Not Reported | secondary_gleason_grade || Not Reported | secondhand_smoke_as_child || Not Reported | sequence_duplication_levels || Not Reported | sequence_length_distribution || Not Reported | site_of_resection_or_biopsy || Not Reported | sites_of_involvement || Not Reported | smoking_frequency || Not Reported | specimen_type || Not Reported | spindle_cell_percent_range || Not Reported | staining_intensity_scale || Not Reported | staining_intensity_value || Not Reported | supratentorial_localization || Not Reported | synchronous_malignancy || Not Reported | test_analyte_type || Not Reported | test_result || Not Reported | test_units || Not Reported | test_value_range || Not Reported | therapeutic_agents || Not Reported | therapeutic_levels_achieved || Not Reported | therapeutic_target_level || Not Reported | time_between_waking_and_first_smoke || Not Reported | timepoint_category || Not Reported | tissue_or_organ_of_origin || Not Reported | tissue_type || Not Reported | tobacco_smoking_status || Not Reported | transglottic_extension || Not Reported | treatment_anatomic_sites || Not Reported | treatment_dose_units || Not Reported | treatment_effect || Not Reported | treatment_effect_indicator || Not Reported | treatment_emergent_adverse_event || Not Reported | treatment_frequency || Not Reported | treatment_intent_type || Not Reported | treatment_outcome || Not Reported | treatment_type || Not Reported | tumor_confined_to_organ_of_origin || Not Reported | tumor_depth_descriptor || Not Reported | tumor_descriptor || Not Reported | tumor_focality || Not Reported | tumor_grade || Not Reported | tumor_grade_category || Not Reported | tumor_infiltrating_lymphocytes || Not Reported | tumor_infiltrating_macrophages || Not Reported | tumor_regression_grade || Not Reported | tumor_shape || Not Reported | type_of_smoke_exposure || Not Reported | uicc_clinical_m || Not Reported | uicc_clinical_n || Not Reported | uicc_clinical_stage || Not Reported | uicc_clinical_t || Not Reported | uicc_pathologic_m || Not Reported | uicc_pathologic_n || Not Reported | uicc_pathologic_stage || Not Reported | uicc_pathologic_t || Not Reported | uicc_staging_system_edition || Not Reported | ulceration_indicator || Not Reported | undescended_testis_corrected || Not Reported | undescended_testis_corrected_age_range || Not Reported | undescended_testis_corrected_laterality || Not Reported | undescended_testis_corrected_method || Not Reported | undescended_testis_history || Not Reported | undescended_testis_history_laterality || Not Reported | variant_origin || Not Reported | variant_type || Not Reported | vascular_invasion_present || Not Reported | vascular_invasion_type || Not Reported | viral_hepatitis_serology_tests || Not Reported | vital_status || Not Reported | weiss_assessment_findings || Not Reported | weiss_assessment_score || Not Reported | who_cns_grade || Not Reported | who_nte_grade || Not Reported | wilms_tumor_histologic_subtype || Not Reported | zone_of_origin_prostate || Not Reported | zygosity || not reported | classification_of_tumor || not reported | ethnicity || not reported | gender || not reported | last_known_disease_status || not reported | prior_malignancy || not reported | progression_or_recurrence || not reported | race || not reported | relationship_gender || not reported | relative_with_cancer_history || not reported | treatment_or_therapy || not reported | vital_status	C102562 || C102704 || C103339 || C104014 || C104015 || C104017 || C104018 || C104023 || C104027 || C105721 || C106304 || C106317 || C106541 || C106551 || C111067 || C111073 || C112400 || C121007 || C123560 || C125738 || C125904 || C126378 || C127762 || C127768 || C127772 || C129439 || C13202 || C133427 || C13355 || C133706 || C138899 || C139007 || C140258 || C140259 || C140262 || C140266 || C141342 || C142346 || C143151 || C15256 || C154881 || C15599 || C156421 || C156422 || C157103 || C157110 || C157233 || C157410 || C157425 || C157437 || C158874 || C159229 || C159643 || C160720 || C160827 || C160837 || C160996 || C16124 || C161320 || C16165 || C162221 || C164057 || C16457 || C164683 || C16564 || C166199 || C166229 || C166276 || C16687 || C168796 || C17001 || C17049 || C17103 || C171253 || C17140 || C171435 || C173263 || C173544 || C17357 || C173595 || C17369 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177569 || C177570 || C177571 || C177572 || C177576 || C177577 || C177578 || C177579 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177596 || C177597 || C177598 || C177599 || C177600 || C177601 || C177602 || C177603 || C177604 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177616 || C177617 || C177619 || C177620 || C177621 || C177622 || C177624 || C177626 || C177627 || C177628 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C17953 || C181720 || C181723 || C182060 || C182097 || C182099 || C182101 || C182102 || C182109 || C182312 || C18304 || C185074 || C185261 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C188000 || C188372 || C188373 || C188387 || C188388 || C188406 || C188408 || C188409 || C188411 || C188415 || C188429 || C188446 || C188448 || C188452 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C198091 || C198092 || C198095 || C198101 || C198107 || C198127 || C198131 || C198139 || C198194 || C198195 || C198198 || C198199 || C198200 || C198201 || C198204 || C198206 || C199145 || C200441 || C200442 || C200444 || C200446 || C200469 || C200473 || C200474 || C200476 || C200477 || C20118 || C202137 || C202138 || C202139 || C202140 || C202155 || C202157 || C202158 || C202159 || C202160 || C206478 || C206479 || C206480 || C211836 || C211838 || C211839 || C211840 || C211841 || C211842 || C2480 || C25185 || C25188 || C25193 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C2873 || C29878 || C2991 || C33027 || C3420 || C35529 || C35886 || C36037 || C36292 || C38032 || C38114 || C39694 || C4086 || C41331 || C42578 || C43283 || C45824 || C45902 || C4809 || C48603 || C48604 || C48605 || C49236 || C50995 || C54398 || C574 || C67415 || C70700 || C70713 || C70729 || C81180 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C93711 || C94536 || C94811 || C95149 || C97229 || C97926 || C99532	inpc_grade || reason_treatment_not_given || pretreatment || weiss_assessment_score || weiss_assessment_findings || ensat_pathologic_stage || ensat_pathologic_t || ensat_pathologic_n || ensat_clinical_m || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || number_of_pregnancies || ajcc_serum_tumor_markers || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || double_hit_lymphoma || alcohol_intensity || staining_intensity_value || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || inrg_stage || chromosome_arm || mismatch_repair_mutation || double_expressor_lymphoma || iss_stage || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || gleason_grade_group || masaoka_stage || hysterectomy_type || ulceration_indicator || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || exposure_type || hpv_strain || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || eye_color || primary_site || calgb_risk_group || lymph_nodes_removed || lymphatic_invasion_present || satellite_nodule_present || extranodal_extension || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || type_of_smoke_exposure || comorbidities || treatment_emergent_adverse_event || ethnicity || treatment_dose_units || tumor_descriptor || reason_treatment_ended || histone_family || pathogenicity || ploidy || race || risk_factors || second_gene_symbol || environmental_tobacco_smoke_exposure || biospecimen_anatomic_site || sites_of_involvement || variant_type || gender || gene_symbol || imaging_type || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || margins_involved_site || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || method_of_diagnosis || evidence_of_recurrence_type || dysplasia_degree || country_of_residence_at_enrollment || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || necrosis_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || variant_origin || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serology_tests || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || initial_disease_status || last_known_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || secondhand_smoke_as_child || smoking_frequency || time_between_waking_and_first_smoke || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || education_level || consistent_pathology_review || undescended_testis_corrected_laterality || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || undescended_testis_corrected_method || undescended_testis_history_laterality || adrenal_hormone || imaging_anatomic_site || clonality || history_of_tumor_type || extraocular_nodule_size || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || alcohol_frequency || exposure_source || asbestos_exposure_type || clinical_trial_indicator || drug_category || uicc_clinical_m || uicc_clinical_n || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_m || uicc_pathologic_n || uicc_pathologic_stage || uicc_pathologic_t || zone_of_origin_prostate || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || cancer_detection_method || chemical_exposure_type || evidence_of_progression_type || extracapsular_extension || first_event || lymph_node_dissection_site || mutation_codon || peritoneal_washing_results || residual_tumor_measurement || risk_factor_method_of_diagnosis || therapeutic_levels_achieved || test_value_range || therapeutic_target_level || timepoint_category || tumor_grade_category || uicc_staging_system_edition || imaging_findings || country_of_birth || contiguous_organ_invaded || measurement_type || melanoma_known_primary || relative_smoker || tumor_depth_descriptor || tumor_shape || tumor_infiltrating_lymphocytes || tumor_infiltrating_macrophages || international_prognostic_index || extracapsular_extension_present || extrathyroid_extension || histologic_progression_type || micrometastasis_present || nononcologic_therapeutic_agents || oxygen_use_indicator || oxygen_use_type || radiosensitizing_agent || staining_intensity_scale || prescribed_dose_units || hormonal_replacement_therapy_status || prcc_type || histologic_progression || undescended_testis_corrected_age_range || epithelioid_cell_percent_range || extrascleral_extension_present || intratubular_germ_cell_neoplasia_present || spindle_cell_percent_range || scan_tracer_used || laterality || marital_status || occupation_type || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || aneuploidy || relative_with_cancer_history || disease_type || lymph_node_involved_site || chromosomal_lymph_node_involvement || morphologic_architectural_pattern || tumor_confined_to_organ_of_origin || test_result || treatment_effect || route_of_administration || sarcomatoid_present || dysplasia_type || adverse_event || measurement_unit || ann_arbor_b_symptoms_described || zygosity || alcohol_type || residual_disease || residual_tumor || primary_gleason_grade || secondary_gleason_grade || gleason_grade_tertiary || treatment_or_therapy || disease_response || treatment_intent_type || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || specimen_type || treatment_anatomic_sites || relative_deceased || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || adverse_event_grade || best_overall_response || clark_level || ishak_fibrosis_score || embolic_agent || molecular_consequence || diabetes_treatment_type
C	C177537	GDC Value Terminology	C4376	Renal Failure	An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood.	Renal Insufficiency | comorbidities || Renal Insufficiency | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C4503	Hereditary Breast Carcinoma	Breast carcinoma that has developed in relatives of patients with history of breast carcinoma.	Hereditary Breast Cancer | comorbidities || Hereditary Breast Cancer | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C48658	Indeterminate	Cannot distinguish between two or more possible values in the current context.	Indeterminant | lymph_node_involvement || Indeterminant | margin_status || Indeterminate | imaging_result || Indeterminate | margin_status || Indeterminate | method_of_sample_procurement || Indeterminate | non_nodal_regional_disease || Indeterminate | ovarian_surface_involvement || Indeterminate | satellite_nodule_present	C123560 || C160827 || C176708 || C177597 || C177600 || C35529 || C70700	margin_status || satellite_nodule_present || imaging_result || non_nodal_regional_disease || ovarian_surface_involvement || lymph_node_involvement || method_of_sample_procurement
C	C177537	GDC Value Terminology	C4922	Diverticulosis	A finding indicating the presence of multiple pouches, usually in the colonic or gastric wall.	Diverticulosis | comorbidities || Diverticulosis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C49487	No	The non-affirmative response to a question.	No | adrenal_hormone || No | alcohol_history || No | anaplasia_present || No | ann_arbor_b_symptoms || No | ann_arbor_extranodal_involvement || No | barretts_esophagus_goblet_cells_present || No | bone_marrow_malignant_cells || No | chemo_concurrent_to_radiation || No | clinical_trial_indicator || No | columnar_mucosa_present || No | consistent_pathology_review || No | diagnosis_pathologically_confirmed || No | double_expressor_lymphoma || No | double_hit_lymphoma || No | environmental_tobacco_smoke_exposure || No | esophageal_columnar_metaplasia_present || No | extracapsular_extension_present || No | extrascleral_extension_present || No | gastric_esophageal_junction_involvement || No | goblet_cells_columnar_mucosa_present || No | haart_treatment_indicator || No | hepatitis_sustained_virological_response || No | histologic_progression || No | history_of_tumor || No | hormonal_replacement_therapy_status || No | intratubular_germ_cell_neoplasia_present || No | lost_to_followup || No | lymph_nodes_removed || No | lymphatic_invasion_present || No | melanoma_known_primary || No | metaplasia_present || No | micrometastasis_present || No | mismatch_repair_mutation || No | necrosis_present || No | non_nodal_tumor_deposits || No | normal_tumor_genotype_snp_match || No | oxygen_use_indicator || No | parent_with_radiation_exposure || No | perineural_invasion_present || No | pregnant_at_diagnosis || No | premature_at_birth || No | prior_treatment || No | progression_or_recurrence || No | radiosensitizing_agent || No | relative_deceased || No | relative_smoker || No | rhabdoid_present || No | risk_factor_treatment || No | sarcomatoid_present || No | secondhand_smoke_as_child || No | synchronous_malignancy || No | therapeutic_levels_achieved || No | treatment_effect_indicator || No | tumor_confined_to_organ_of_origin || No | ulceration_indicator || No | undescended_testis_corrected || No | undescended_testis_history || No | vascular_invasion_present || no | prior_malignancy || no | progression_or_recurrence || no | relative_with_cancer_history || no | treatment_or_therapy	C112400 || C125904 || C127768 || C127772 || C133706 || C138899 || C141342 || C154881 || C159643 || C159824 || C160720 || C16124 || C161320 || C16165 || C17140 || C177585 || C177586 || C177587 || C177589 || C177590 || C177591 || C177592 || C177593 || C177595 || C177596 || C177598 || C177599 || C177601 || C177602 || C177603 || C177619 || C177626 || C177634 || C177638 || C178286 || C181720 || C182060 || C182097 || C182099 || C182109 || C188387 || C18849 || C198198 || C200446 || C200469 || C202137 || C202140 || C202157 || C202159 || C206479 || C211836 || C211840 || C211841 || C29878 || C36037 || C39694 || C49236 || C81180 || C81229	premature_at_birth || double_hit_lymphoma || perineural_invasion_present || vascular_invasion_present || mismatch_repair_mutation || double_expressor_lymphoma || chemo_concurrent_to_radiation || ulceration_indicator || lymph_nodes_removed || lost_to_followup || lymphatic_invasion_present || prior_treatment || synchronous_malignancy || haart_treatment_indicator || environmental_tobacco_smoke_exposure || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || metaplasia_present || necrosis_present || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || pregnant_at_diagnosis || secondhand_smoke_as_child || hepatitis_sustained_virological_response || treatment_effect_indicator || anaplasia_present || consistent_pathology_review || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || adrenal_hormone || clinical_trial_indicator || history_of_tumor || prior_malignancy || therapeutic_levels_achieved || melanoma_known_primary || relative_smoker || extracapsular_extension_present || micrometastasis_present || oxygen_use_indicator || radiosensitizing_agent || hormonal_replacement_therapy_status || histologic_progression || extrascleral_extension_present || intratubular_germ_cell_neoplasia_present || relative_with_cancer_history || tumor_confined_to_organ_of_origin || sarcomatoid_present || treatment_or_therapy || relative_deceased || alcohol_history
C	C177537	GDC Value Terminology	C49488	Yes	The affirmative response to a question.	Yes | adrenal_hormone || Yes | alcohol_history || Yes | anaplasia_present || Yes | ann_arbor_b_symptoms || Yes | ann_arbor_extranodal_involvement || Yes | barretts_esophagus_goblet_cells_present || Yes | bone_marrow_malignant_cells || Yes | chemo_concurrent_to_radiation || Yes | clinical_trial_indicator || Yes | columnar_mucosa_present || Yes | consistent_pathology_review || Yes | diagnosis_pathologically_confirmed || Yes | double_expressor_lymphoma || Yes | double_hit_lymphoma || Yes | environmental_tobacco_smoke_exposure || Yes | esophageal_columnar_metaplasia_present || Yes | extracapsular_extension_present || Yes | extrascleral_extension_present || Yes | gastric_esophageal_junction_involvement || Yes | goblet_cells_columnar_mucosa_present || Yes | haart_treatment_indicator || Yes | hepatitis_sustained_virological_response || Yes | histologic_progression || Yes | history_of_tumor || Yes | hormonal_replacement_therapy_status || Yes | intratubular_germ_cell_neoplasia_present || Yes | lost_to_followup || Yes | lymph_nodes_removed || Yes | lymphatic_invasion_present || Yes | melanoma_known_primary || Yes | metaplasia_present || Yes | micrometastasis_present || Yes | mismatch_repair_mutation || Yes | necrosis_present || Yes | non_nodal_tumor_deposits || Yes | normal_tumor_genotype_snp_match || Yes | oxygen_use_indicator || Yes | parent_with_radiation_exposure || Yes | perineural_invasion_present || Yes | pregnant_at_diagnosis || Yes | premature_at_birth || Yes | prior_treatment || Yes | progression_or_recurrence || Yes | radiosensitizing_agent || Yes | relative_deceased || Yes | relative_smoker || Yes | rhabdoid_present || Yes | risk_factor_treatment || Yes | sarcomatoid_present || Yes | secondhand_smoke_as_child || Yes | synchronous_malignancy || Yes | therapeutic_levels_achieved || Yes | treatment_effect_indicator || Yes | tumor_confined_to_organ_of_origin || Yes | ulceration_indicator || Yes | undescended_testis_corrected || Yes | undescended_testis_history || Yes | vascular_invasion_present || yes | prior_malignancy || yes | progression_or_recurrence || yes | relative_with_cancer_history || yes | treatment_or_therapy	C112400 || C125904 || C127768 || C127772 || C133706 || C138899 || C141342 || C154881 || C159643 || C159824 || C160720 || C16124 || C161320 || C16165 || C17140 || C177585 || C177586 || C177587 || C177589 || C177590 || C177591 || C177592 || C177593 || C177595 || C177596 || C177598 || C177599 || C177601 || C177602 || C177603 || C177619 || C177626 || C177634 || C177638 || C178286 || C181720 || C182060 || C182097 || C182099 || C182109 || C188387 || C18849 || C198198 || C200446 || C200469 || C202137 || C202140 || C202157 || C202159 || C206479 || C211836 || C211840 || C211841 || C29878 || C36037 || C39694 || C49236 || C81180 || C81229	premature_at_birth || double_hit_lymphoma || perineural_invasion_present || vascular_invasion_present || mismatch_repair_mutation || double_expressor_lymphoma || chemo_concurrent_to_radiation || ulceration_indicator || lymph_nodes_removed || lost_to_followup || lymphatic_invasion_present || prior_treatment || synchronous_malignancy || haart_treatment_indicator || environmental_tobacco_smoke_exposure || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || metaplasia_present || necrosis_present || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || pregnant_at_diagnosis || secondhand_smoke_as_child || hepatitis_sustained_virological_response || treatment_effect_indicator || anaplasia_present || consistent_pathology_review || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || adrenal_hormone || clinical_trial_indicator || history_of_tumor || prior_malignancy || therapeutic_levels_achieved || melanoma_known_primary || relative_smoker || extracapsular_extension_present || micrometastasis_present || oxygen_use_indicator || radiosensitizing_agent || hormonal_replacement_therapy_status || histologic_progression || extrascleral_extension_present || intratubular_germ_cell_neoplasia_present || relative_with_cancer_history || tumor_confined_to_organ_of_origin || sarcomatoid_present || treatment_or_therapy || relative_deceased || alcohol_history
C	C177537	GDC Value Terminology	C50466	Atrial Fibrillation	A disorder characterized by an electrocardiographic finding of a supraventricular arrhythmia characterized by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape and timing and are accompanied by an irregular ventricular response. (CDISC)	Atrial Fibrillation | comorbidities || Atrial Fibrillation | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C50625	Ischemic Heart Disease	A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).	Ischemic Heart Disease | comorbidities || Ischemic Heart Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C50791	Urinary Tract Infection	A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine.	Urinary Tract Infection | comorbidities || Urinary Tract Infection | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C51138	Lesion with Diameter Greater than 2 cm	A lesion measuring more than 2 cm in greatest dimension.	Macroscopic (greater than 2cm) | largest_extrapelvic_peritoneal_focus	C178289	largest_extrapelvic_peritoneal_focus
C	C177537	GDC Value Terminology	C51302	Hereditary Leiomyomatosis and Renal Cell Carcinoma	An autosomal dominant inherited syndrome caused by germline mutations in the FH gene. It is characterized by predisposition to renal cell carcinoma, leiomyomas of the skin and uterus, and leiomyosarcoma of the uterus.	Hereditary Leiomyomatosis and Renal Cell Carcinoma | comorbidities || Hereditary Leiomyomatosis and Renal Cell Carcinoma | risk_factors || Hereditary leiomyomatosis & RCC-associated renal cell carcinoma | primary_diagnosis	C16457 || C17103 || C177621	comorbidities || risk_factors || primary_diagnosis
C	C177537	GDC Value Terminology	C53696	Lesion with Diameter of 2 cm or Less	A semi-quantitative finding indicating that the largest diameter for a lesion is less than or equal to 2 cm.	Macroscopic (2cm or less) | largest_extrapelvic_peritoneal_focus	C178289	largest_extrapelvic_peritoneal_focus
C	C177537	GDC Value Terminology	C54722	Low	A minimum level or position or degree; less than normal in degree, intensity or amount.	Low | test_result	C36292	test_result
C	C177537	GDC Value Terminology	C5541	High Grade Prostatic Intraepithelial Neoplasia	Prostatic intraepithelial neoplasia characterized by the presence of morphologically malignant cells lining the acini and ducts.  The malignant cells are enlarged, contain prominent nucleoli, and have increased nuclear/cytoplasmic ratio.  The malignant cells may grow within the ducts and acini in four architectural patterns: flat, tufting, micropapillary, and cribriform.  The presence of high grade prostatic intraepithelial neoplasia in needle biopsy is a risk factor for the subsequent detection of carcinoma on repeat biopsy.	High-grade Prostatic Intraepithelial Neoplasia (PIN) | comorbidities || High-grade Prostatic Intraepithelial Neoplasia (PIN) | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C5665	Atypical Adenomatous Lung Hyperplasia	A preinvasive lesion in the lung. It is characterized by the presence of a small, localized proliferation of mildly to moderately atypical type II pneumocytes and/or Clara cells lining alveolar walls and sometimes respiratory bronchioles.	Adenosis (Atypical Adenomatous Hyperplasia) | comorbidities || Adenosis (Atypical Adenomatous Hyperplasia) | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C61272	Glycogen Storage Disease	An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.	Glycogen Storage Disease | comorbidities || Glycogen Storage Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C62586	Cryptogenic Organizing Pneumonia	A form of organizing pneumonia with a non-infectious etiology. Excessive proliferation of granulation tissue occurs in alveolar ducts and alveoli and primarily causes injury to alveolar walls, but bronchioles may be affected.	Cryptogenic Organizing Pneumonia | comorbidities || Cryptogenic Organizing Pneumonia | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C6496	Myxofibrosarcoma	A malignant fibroblastic neoplasm arising from the soft tissue. It is characterized by the presence of spindle-shaped cells, cellular pleomorphism, thin-walled blood vessels, fibrous septa, and myxoid stroma.	8811/3 | morphology || Fibromyxosarcoma | primary_diagnosis || Myxofibrosarcoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C65173	Non-Keratinizing Large Cell Squamous Cell Carcinoma	A squamous cell carcinoma composed of large atypical cells without morphologic evidence of keratin production.	8072/3 | morphology || Epidermoid carcinoma, large cell, nonkeratinizing | primary_diagnosis || Squamous cell carcinoma, large cell, nonkeratinizing, NOS | primary_diagnosis || Squamous cell carcinoma, nonkeratinizing, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C65175	Non-Keratinizing Small Cell Squamous Cell Carcinoma	A squamous cell carcinoma composed of small atypical cells without morphologic evidence of keratin production.	8073/3 | morphology || Epidermoid carcinoma, small cell, nonkeratinizing | primary_diagnosis || Squamous cell carcinoma, small cell, nonkeratinizing | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C6875	Large Cell Neuroendocrine Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation composed of malignant large cells.	8013/3 | morphology || Large cell neuroendocrine carcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C6882	Micropapillary Serous Carcinoma	An adenocarcinoma that usually arises from the ovary. It is characterized by the presence of complex micropapillary structures covered by round and cuboidal cells with a high nuclear to cytoplasmic ratio.	8460/3 | morphology || Micropapillary serous carcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C68962	Talfirastide	A synthetic heptapeptide identical to endogenous angiotensin-(1-7) with vasodilator and antiproliferative activities. Talfirastide may inhibit cyclooxygenase 2 (COX-2) and the production of proinflammatory prostaglandins and may activate the angiotensin-(1-7) receptor Mas, resulting in diminished tumor cell proliferation. Activation of the angiotensin-(1-7) receptor Mas, a G-protein coupled, seven transmembrane protein, may down-regulate the phosphorylation and activation of Erk1 and Erk2 in the Erk1/Erk2 MAPK signaling pathway. In the renin-angiotensin system, the vasodilating activity of angiotensin- (1-7), hydrolysed from angiotensin II by the type I transmembrane metallopeptidase and carboxypeptidase angiotensin converting enzyme 2 (ACE2) in vivo, counteracts the vasoconstricting activity of angiotensin II.	Therapeutic Angiotensin-(1-7) | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C6996	Uterine Corpus Adenomyosis	The growth of endometrial tissue inside the muscular wall of the uterine corpus. Clinical manifestations include pain, dysmenorrhea, and menorrhagia.	Adenomyosis | additional_pathology_findings || Adenomyosis | comorbidities || Adenomyosis | risk_factors	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C70430	Zero	A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.	0 | number_of_pregnancies || 0 | peripancreatic_lymph_nodes_positive || 0 | weiss_assessment_score || 0% | epithelioid_cell_percent_range || 0% | spindle_cell_percent_range	C104014 || C106551 || C178276 || C211839 || C211842	weiss_assessment_score || number_of_pregnancies || peripancreatic_lymph_nodes_positive || epithelioid_cell_percent_range || spindle_cell_percent_range
C	C177537	GDC Value Terminology	C73705	Intermediate	Lying between two extremes in time or space or degree.	Intermediate | test_result	C36292	test_result
C	C177537	GDC Value Terminology	C74544	Teloxantrone Hydrochloride	The hydrochloride salt of an anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis.	Teloxantrone Hydrochloride | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C7569	Thymus Carcinoma	A diverse group of carcinomas of the thymus gland, previously known as thymoma type C.  It includes morphologic variants derived from purely epithelial cells, as well as from cells with neuroendocrine differentiation.	8586/3 | morphology || Thymic carcinoma, NOS | primary_diagnosis || Thymoma, type C | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C7695	Primary Peritoneal Serous Papillary Adenocarcinoma	A rare serous papillary adenocarcinoma that arises from the lining of the peritoneum. It affects females.	8461/3 | morphology || Primary serous papillary carcinoma of peritoneum | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C79596	Hepatic Encephalopathy	A constellation of signs and symptoms characterized by changes in personality, consciousness, and reflexes, resulting from neuropsychiatric abnormalities secondary to liver failure without evidence of other brain disease.	Hepatic Encephalopathy | comorbidities || Hepatic Encephalopathy | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C80078	Chronic Kidney Disease	Impairment of the renal function secondary to chronic kidney damage persisting for three or more months.	Chronic Kidney Disease | comorbidities || Chronic Kidney Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C80326	B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified	B lymphoblastic leukemias/lymphomas characterized by the absence of recurrent genetic abnormalities.	9811/3 | morphology || B lymphoblastic leukemia/lymphoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C80331	B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1	A precursor lymphoid neoplasm which is composed of B lymphoblasts and carries a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.	9812/3 | morphology || B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C80332	B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged	A precursor lymphoid neoplasm which is composed of B lymphoblasts and carries a translocation between the KMT2A gene at 11q23.3 and another gene partner resulting in the production of an KMT2A related fusion protein.	9813/3 | morphology || B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C80334	B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1	A precursor lymphoid neoplasm which is composed of B lymphoblasts and carries a translocation between the TEL gene on chromosome 12 and the AML1 gene on chromosome 21, (p13.2;q22.1). It results in the production of the TEL-AML1 (ETV6-RUNX1) fusion protein. It has a favorable clinical outcome.	9814/3 | morphology || B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C80335	Hyperdiploid B Lymphoblastic Leukemia/Lymphoma	A precursor lymphoid neoplasm composed of B lymphoblasts which contain more than 50 and usually less than 66 chromosomes. It has a favorable clinical outcome.	9815/3 | morphology || B lymphoblastic leukemia/lymphoma with hyperdiploidy | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C80338	Hypodiploid B Lymphoblastic Leukemia/Lymphoma	A precursor lymphoid neoplasm composed of B lymphoblasts which contain less than 46 chromosomes. It has an unfavorable clinical outcome.	9816/3 | morphology || B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL) | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C80340	B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH	A precursor lymphoid neoplasm which is composed of B lymphoblasts and carries a translocation between the IL3 gene on chromosome 5 and the IGH locus on chromosome 14, (q31.1;q32.3). It results in eosinophilia.	9817/3 | morphology || B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C80341	B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1	A precursor lymphoid neoplasm which is composed of B lymphoblasts and carries a translocation between the E2A gene on chromosome 19 and the PBX1 gene on chromosome 1.	9818/3 | morphology || B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C80385	Dyslipidemia	A lipoprotein metabolism disorder characterized by decreased levels of high-density lipoproteins, or elevated levels of plasma cholesterol, low-density lipoproteins and/or triglycerides.	Dyslipidemia | comorbidities || Dyslipidemia | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C82892	Hemochromatosis	Accumulation of iron in internal organs.	Hemochromatosis | comorbidities || Hemochromatosis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C82978	Chronic Hepatitis	An active inflammatory process affecting the liver for more than six months. Causes include viral infections, autoimmune disorders, drugs, and metabolic disorders.	Hepatitis, Chronic | comorbidities || Hepatitis, Chronic | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C82980	Fungal Colonization	Collection of fungal organisms in an anatomic site or medical device.	Colonization, Fungal | comorbidities || Colonization, Fungal | risk_factors || Colonization; fungal | additional_pathology_findings	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C83119	Physical Examination Finding	The result of an evaluation of the body and its functions using visual inspection, palpation, percussion, or auscultation that is performed to determine the presence, absence, or degree of a condition.	Physical Examination | evidence_of_progression_type || Physical Examination | evidence_of_recurrence_type	C177577 || C198095	evidence_of_recurrence_type || evidence_of_progression_type
C	C177537	GDC Value Terminology	C8360	Intestinal Metaplasia	A morphologic finding indicating the replacement of epithelial tissue outside the intestines by intestinal-type epithelium.	Intestinal Metaplasia | comorbidities || Intestinal Metaplasia | risk_factors || Intestinal metaplasia | additional_pathology_findings	C158809 || C16457 || C17103	additional_pathology_findings || comorbidities || risk_factors
C	C177537	GDC Value Terminology	C8366	Intraepithelial Neoplasia	A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as low grade (mild dysplasia) or high grade (moderate or severe dysplasia).	Epithelial | dysplasia_type || Epithelial Dysplasia | comorbidities || Epithelial Dysplasia | risk_factors || Epithelial dysplasia | additional_pathology_findings	C158809 || C16457 || C17103 || C4086	additional_pathology_findings || comorbidities || risk_factors || dysplasia_type
C	C177537	GDC Value Terminology	C84397	Alpha-1 Antitrypsin Deficiency	A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.	Alpha-1 Antitrypsin Deficiency | comorbidities || Alpha-1 Antitrypsin Deficiency | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C84444	Nonalcoholic Fatty Liver Disease	A term referring to fatty replacement of the hepatic parenchyma which is not related to alcohol use.	Nonalcoholic Fatty Liver Disease | comorbidities || Nonalcoholic Fatty Liver Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C84729	Gilbert Syndrome	An autosomal recessive inherited disorder characterized by unconjugated hyperbilirubinemia, resulting in harmless intermittent jaundice.	Gilbert's Syndrome | comorbidities || Gilbert's Syndrome | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C84860	Ucalolictide	A water-soluble, positively charged fusion protein consisting of a luteinizing hormone releasing hormone (LHRH) receptor-targeting ligand conjugated to the membrane-disrupting peptide CLIP 71 with membrane-disrupting and potential antineoplastic activities. The LHRH ligand moiety of ucalolictide specifically binds to LHRH receptors, which are upregulated on a variety of human cancer cell types. Subsequently, the positively charged CLIP 71 moiety of this agent interacts with the negatively charged membrane on the cancer cell surface, which may result in cell membrane disruption and cell lysis.	Membrane-Disrupting Peptide EP-100 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C84932	Neurocysticercosis	A parasitic infection with tapeworms of the genus Taenia affecting the brain. It is manifested with seizures and headaches.	Neurocystericerosis | comorbidities || Neurocysticercosis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C85051	Rubella Infection	A viral infection caused by the rubella virus. It is initially manifested with flu-like symptoms that last one or two days, followed by the development of a characteristic red rash which lasts from one to five days. The rash first appears in the neck and face. It subsequently spreads to the rest of the body.	Rubella | comorbidities || Rubella | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C8960	Hereditary Kidney Oncocytoma	An inherited condition characterized by the development of kidney oncocytomas which are often bilateral and multifocal.  This condition may be connected to Birt-Hogg-Dube syndrome.	Hereditary Kidney Oncocytoma | comorbidities || Hereditary Kidney Oncocytoma | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C92188	Seasonal Allergic Rhinitis	Allergic rhinitis caused by outdoor allergens.	Hay Fever | comorbidities || Hay Fever | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C9222	Hereditary Papillary Renal Cell Carcinoma	A familial carcinoma inherited in an autosomal dominant trait.  It is characterized by the development of multiple, bilateral papillary renal cell carcinomas.  The carcinomas range from microscopic lesions to clinically symptomatic tumors.  It is associated with activating mutations of the MET oncogene.	Hereditary Papillary Renal Cell Carcinoma | comorbidities || Hereditary Papillary Renal Cell Carcinoma | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C9283	Lymphocyte-Depleted Classic Hodgkin Lymphoma	A diffuse subtype of classic Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)	9653/3 | morphology || 9654/3 | morphology || 9655/3 | morphology || Classical Hodgkin lymphoma, lymphocyte depletion, NOS | primary_diagnosis || Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis | primary_diagnosis || Classical Hodgkin lymphoma, lymphocyte depletion, reticular | primary_diagnosis || Hodgkin lymphoma, lymphocyte depletion, NOS | primary_diagnosis || Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis | primary_diagnosis || Hodgkin lymphoma, lymphocyte depletion, reticular | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C94575	Scarlet Fever	A streptococcal infection, mainly occurring among children, that is characterized by a red skin rash, sore throat, and fever.	Scarlet Fever | comorbidities || Scarlet Fever | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C95701	Ribociclib	An orally available inhibitor of the cyclin-dependent kinases (CDKs) 4 and 6, with antineoplastic activity. Upon oral administration, ribociclib specifically targets, binds to and inhibits CDK4 and CDK6. This inhibits the cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, which inhibits phosphorylation of the retinoblastoma (Rb) protein. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle dysregulation.	Ribociclib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C96768	High Grade Liver Dysplastic Nodule	A hepatic dysplastic nodule characterized by the presence of high grade atypical cellular changes.	High Grade Liver Dysplastic Nodule | comorbidities || High Grade Liver Dysplastic Nodule | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C96770	Low Grade Liver Dysplastic Nodule	A hepatic dysplastic nodule characterized by the presence of low grade atypical cellular changes.	Low Grade Liver Dysplastic Nodule | comorbidities || Low Grade Liver Dysplastic Nodule | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C98640	Tyrosinemia	An autosomal recessive inherited metabolic disorder caused by mutations in the FAH, HPD, and TAT genes. It is characterized by deficiency of one of the enzymes that are involved in the metabolism of tyrosine. It results in elevated blood tyrosine levels and accumulation of tyrosine and its byproducts in the liver, kidney, nervous system and other organs.	Tyrosinemia | comorbidities || Tyrosinemia | risk_factors	C16457 || C17103	comorbidities || risk_factors